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Abstract
Purpose—In 2007 the two senior authors wrote a review on
the structure and function of the endothelial glycocalyx layer
(Weinbaum in Annu Rev Biomed Eng 9:121–167, 2007).
Since then there has been an explosion of interest in this
hydrated gel-like structure that coats the luminal surface of
endothelial cells that line our vasculature due to its important
functions in (A) basic vascular physiology and (B) vascular
related diseases. This review will highlight the major
advances that have occurred since our 2007 paper.
Methods—A literature search mainly focusing on the role of
the glycocalyx in the two major areas described above was
performed using electronic databases.
Results—In part (A) of this review, the new formulation of
the century old Starling principle, now referred to as the
Michel–Weinbaum glycoclayx model or revised Starling
hypothesis, is described including new subtleties and physiological ramiﬁcations. New insights into mechanotransduction and release of nitric oxide due to ﬂuid shear stress sensed
by the glycocalyx are elaborated. Major advances in
understanding the organization and function of glycocalyx
components, and new techniques for measuring both its
thickness and spatio-chemical organization based on super
resolution, stochastic optical reconstruction microscopy
(STORM) are presented. As discussed in part (B) of this
review, it is now recognized that artery wall stiffness
associated with hypertension and aging induces glycocalyx
degradation, endothelial dysfunction and vascular disease. In
addition to atherosclerosis and cardiovascular diseases, the
glycocalyx plays an important role in lifestyle related diseases
(e.g., diabetes) and cancer. Infectious diseases including
sepsis, Dengue, Zika and Corona viruses, and malaria also
involve the glycocalyx. Because of increasing recognition of
the role of the glycocalyx in a wide range of diseases, there
has been a vigorous search for methods to protect the
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glycocalyx from degradation or to enhance its synthesis in
disease environments.
Conclusion—As we have seen in this review, many important
developments in our basic understanding of GCX structure,
function and role in diseases have been described since the
2007 paper. The future is wide open for continued GCX
research.
Keywords—Endothelial glycocalyx, Mechanotransduction,
Revised Starling principle, Michel–Weinbaum model, Cancer
cell glycocalyx.

INTRODUCTION
In 2007 the two senior authors and ER Damiano
wrote a highly cited extensive review220 summarizing
what was known at the time of the structure and
function of the endothelial glycocalyx (GCX), the hydrated gel-like structure that coats the luminal surface
of the endothelial cells (EC) that line our vasculature.
This surface matrix is comprised of sulfated proteoglycans—the transmembrane syndecans and the
membrane bound glypicans, with their covalently
bound glycosaminoglycans (GAGs)—heparan sulfate
(HS) and chondroitin sulfate (CS) and the non-sulfated
GAG hyaluronic acid (HA), as well as glycoproteins
and plasma proteins (see Fig. 1). In the past decade
there has been an explosion of interest in this hydrated
gel-like structure due to its important functions in (A)
basic vascular physiology and (B) vascular related
diseases. In Part A we describe how the GCX has led
to a new formulation of the century old Starling
principle195 now referred to as the Michel–Weinbaum
glycoclayx model134,219 or the revised Starling
hypothesis for microvascular ﬂuid exchange. There
have been new insights into mechanotransduction and
the release of nitric oxide (NO) due to ﬂuid shear stress
(FSS),50,60,231 major advances in our understanding of
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FIGURE 1. Simplified schematic of the glycocalyx: cell-surface core proteins and their associated GAGs. Reprinted from Ref. 12.

the structure and function of its various components,159,236 and new techniques for measuring both its
thickness and structural organization based on confocal,232 rapid freeze substitution51 and super resolution
stochastic
optical
reconstruction
microscopy
(STORM).57
In Part B we emphasize that it is now recognized
that artery wall stiﬀness associated with hypertension
and aging induces GCX degradation, endothelial dysfunction and vascular disease.120 In addition to
atherosclerosis and cardiovascular diseases, the GCX
plays an important role in lifestyle related diseases
(e.g., diabetes) and cancer.200 Infectious diseases
including sepsis, Dengue, Zika and Corona viruses,
and malaria also involve the GCX.85,136,167 Because of
increasing recognition of the role of the GCX in a wide
range of diseases, there has been a vigorous search for
methods to protect the GCX from degradation or to
enhance its synthesis in disease environments.200
This review will highlight the major advances outlined above that have occurred since the 2007 paper.

PART A: THE ROLE OF THE GLYCOCALYX
IN VASCULAR PHYSIOLOGY
The Revised Starling Principle: Michel–Weinbaum
Model for Microvascular Fluid Exchange
It is relatively rare that a widely accepted textbook
description of a basic microcirculatory phenomenon
should be challenged after nearly a century of use.
However, this is indeed what happened with the classical Starling hypothesis. While the basic ideas for the
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revised Starling hypothesis were introduced by
Michel134 and Weinbaum219 more than 20 years ago
and the experimental veriﬁcation of the Michel–
Weinbaum model conﬁrmed in mesentery venules in
frog by Hu et al.77 and rat by Adamson et al.1 more
than a decade ago, the widespread acceptance of the
revised hypothesis had not occurred when our 2007
review paper on the GCX was published. Two new
contributions greatly changed this. In 2010 Levick and
Michel108 wrote a Spotlight Review in Cardiovascular
Research which emphasized the clinical importance of
the revised principle and more recently Tom Woodcock, an English clinician, prepared a 27 min video
emphasizing the clinical applications of the revised
hypothesis. This video is the lead entry if you do a
Google search for the Michel–Weinbaum model which
currently has > 100,000 listings.
In the present review, after a brief summary of the
basic diﬀerences between the classic and revised Starling hypothesis, we will highlight the fundamental
diﬀerences between one and two-dimensional models
and the role that trapped microdomains within the
intercellular cleft and at the cleft exit play in the time
dependent response that leads to steady state behavior.
Classic Starling principle
From classic thermodynamic principles one can
write the volume ﬁltration rate per unit area of
endothelial surface or ﬂuid ﬂux Jv/A as a balance
between two forces, the difference in hydrostatic
pressures across a membrane PL  Pi and the difference in oncotic pressures pp  pi where the subscripts
L and i refer to the lumen of the microvessel and the
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interstitial ﬂuid (ISF) in the tissue and pP is the oncotic
pressure of plasma. If this was a simple membrane with
pores one could write the expression for Jv/A as


Jv
¼ L p P L  P i  r p p  pi ;
A

ð1Þ

where Lp and r are the ﬁltration coefﬁcient (or hydraulic conductivity) and osmotic reﬂection coefﬁcient
respectively. The value for r varies between 0 and 1
where 0 would be for a solute much smaller than the
membrane pores and 1 for a plasma protein that was
too large to pass through the pore. Starling realized
that the plasma proteins in the blood and, in particular
the most abundant plasma protein, albumin, would be
greatly hindered and could have a value of r that
would be close to one creating a colloidal oncotic
pressure (COP) for ﬂuid absorption.
For many years it was widely believed that the pores
in the EC monolayer were the intercellular clefts
between adjacent ECs and the constricting pores were
either a matrix in the cleft or associated with the
junction strands between the ECs which served as the
molecular ﬁlter for the plasma proteins. The other
basic assumption in the original hypothesis was that
the COP in the plasma, which could be measured, was
typically 25–28 mmHg and the interstitial COP was
close to zero, though the techniques for measuring the
latter were not developed until the 1980s. Using classic
micropipette measuring techniques developed by
Landis101 and Pappenheimer and Soto-Rivera,161 one
observed that at heart level the typical hydrostatic
pressure on the arterial side of capillaries was
35 mmHg whereas on the venous side a typical value
was 15 mmHg. Thus, when the capillary pressure PL
was > 25 mmHg, water would leave the capillary.
When PL was < 25 mmHg water would be reabsorbed. Thus, several generations of medical students
were taught using Eq. (1) that the plasma that ﬁltered
out of our capillaries when PL was > pP, and was
reabsorbed on the venous side because the COP of our
plasma proteins pP was > PL. This was often referred
to as the non-steady state absorption rule applied at
heart level.
With the advent of reliable techniques for measuring
the COP of the interstitial space it was discovered that
pi was not close to zero but typically 40% of pP. This
extraordinary observation was ﬁrst reported in 1991 by
Levick107 who showed that in the 14 tissues, including
muscle, skin and lung, where pi had been measured
there was no venous absorption. The only exceptions
were the renal cortex, where ﬂuid is continuously taken
up by the peritubular capillaries, and the ascending
vasa recta of the intestinal mucosa where protein free
ﬂuid is continuously secreted by neighboring epithelia,
see Levick and Michel.108

FIGURE 2. Water flux Jv/A of frog mesentery capillary as a
function of capillary pressure in single perfused frog
mesentery capillary. Note the transient state in which
measurements are performed in the first 15 s after the
perfusion pressure is fixed fall along a straight line in which
absorption does occur for pressures below 25 cm H2O,
whereas steady-state measurements performed 2–5 min
after perfusion pressure is fixed show no absorption, but a
low level of filtration at low capillary pressures. Reprinted
from Ref. 108.

Revised Starling Principle
In 1996 Levick and Michel organized a centennial
meeting in London to celebrate the 100th anniversary
of Starling’s classic 1896 paper. The highlight of this
meeting was Levick’s presentation summarizing the
results of his 1991 paper,107 Fig. 2b in Ref. 108.
showing the imbalance of the four classical Starling
pressures when all four terms are measured in the same
tissue and species. On the last day of the meeting Levick, Michel, Curry and Weinbaum met to try and
understand how it was possible that the predictions of
Eq. (1), the classic Starling force balance, could be so
far off in nearly all tissues where these forces had been
measured. This situation was further complicated by
Michel and Phillips now classic experiment135 shown in
Fig. 2 using the Landis technique applied to single
perfused frog mesentery capillaries where the ﬂuid
exchange is measured immediately after raising or
lowering the capillary pressure Pc (transient state) and
after Pc has been held constant for 2–5 min (steady
state). The transient state clearly satisﬁed the classic
Starling force balance when Pc was less than pL
BIOMEDICAL
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FIGURE 3. Schematic of idealized mathematical model showing surface matrix layer, cleft with junction strand, and tissue
regions B and C describing mixing at cleft exit. Dimensions shown are typical of frog mesentery capillary. Reprinted from Ref. 219.

whereas in the steady state Jv/A always returned to a
very low rate of ﬁltration and the curve had the
characteristic shape of a hockey stick. The latter
behavior is described in detail in a recent review by
Curry.37
The shape of the steady state curve in Fig. 2 can be
predicted from a standard one-dimensional convection–diffusion equation in which one requires that in
the far ﬁeld at steady state the tissue concentration Ci
is equal to the ratio of the solute inﬂux from all sources
Js to the total water ﬂux Jv or Ci = Js/Jv. The solute
crossing the endothelium can come not only from ﬂuid
ﬂow though the intercellular clefts but also from
vesicular transport or back loading and Ci varies inversely with Jv. Michel133 realized that as Jv decreased
for the steady state curve in Fig. 2, the concentration
in the tissue would have to approach the concentration
in the plasma and reabsorption would vanish. The
relation between Jv and Pc is non-linear since Jv depends on the extracapillary protein concentration. The
remarkable feature of Michel’s transport equation is
that it could reproduce the shape of the steady state
curve in Fig. 2, with its hockey stick like bend, by
varying the value of a single parameter, the permeability coefﬁcient PA for albumin in the expression for
the Peclet number (Jv/A)(1  r)/PA without ever
including the cleft or its tight junction strand or the
mixing of the ISF at the cleft exit. This unusual
behavior will be explained with the aid of the twodimensional model in Fig. 3 where these features are
included.
What Michel and Weinbaum independently realized
after the 1996 meeting was that the molecular sieve for
plasma proteins, and in particular albumin, did not lie
within structures within the cleft itself but the GCX at
the surface of the endothelium which clearly covered
BIOMEDICAL
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the cleft entrance. This new view was presented by
Michel in his 1997 review paper summarizing the results of the Starling centennial meeting134 and Weinbaum in his 1997 Whitaker Distinguished Lecture at
the annual Meeting of BMES in La Jolla.219 Michel
intuitively realized that the protein concentration gradients within the cleft would be small if the GCX was a
formidable barrier to diffusion and his conceptual
model also included alternate non-convective pathways for larger molecules, such as vesicular transport
which bypassed the clefts entirely. Weinbaum, on the
other hand, shared Michel’s view of the GCX, as the
primary molecular barrier, but was also concerned
about the role of the tight junction strands, since if the
breaks in the strands were small and widely spaced the
convective transport of proteins through the breaks
could greatly impede back diffusion of proteins from
the tissue. If this happened the concentration of the
proteins behind the GCX could differ greatly from the
ISF. Such non-uniformity in behavior would need to
be described by a two-dimensional transport equation
in the cleft.
Weinbaum’s 2-D Transport Model
A sketch of the two-dimensional transport model
used in Weinbaum219 is shown in Fig. 3. Instead of
Eq. (1) one applies the Starling force balance just
across the GCX


Jv
¼ L p P L  P G ð y Þ  r pp  p G ð y Þ :
A

ð2Þ

Here the subscript G refers to the protein concentration just behind the GCX (x = 0 in Fig. 3) and one
allows both the pressure and concentration to vary
with lateral position y behind the GCX. As shown in
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FIGURE 4. Predictions of theoretical model for Pc = 43 cm
H2O for pressure (a), protein concentration profiles at various
locations (b, c) in cleft identified in Fig. 3. (a) and (b) reprinted
from Ref. 219; (c) reprinted from Ref. 78.

Fig. 3 the breaks are periodically arranged along the
length of the junction strand at a distance
2D = 4320 nm, where y = 0 is at the center of each
break whose width 2d is 150 nm. These dimensions are
typical for frog mesentery venules. The model has four
regions, (1) a GCX of thickness 150 nm, (2) the cleft
itself whose depth is 400 nm with a junction strand at
x = 200 nm, (3) a mixing region B of radius 5 lm, the
half distance for the separation of the clefts, and (4) a

FIGURE 5. Predictions of theoretical model for Pc = 15 cm
H2O for pressure (a), protein concentration profiles at various
locations (b, c) in cleft identified in Fig. 3. (a) and (b) Reprinted
from Ref. 219; (c) reprinted from Ref. 78.

mixing region C of width 100 lm, the half distance
between adjacent venules. The concentration in region
C is set at the value Ci = CA = Js/Jv as proposed in
Michel or Ci = 0.4 CL as observed in Levick.107 A
unique feature of the model is that the ﬂow in the cleft
is treated as a 2-D Hele-Shaw ﬂow so that the detailed
pressure distribution and velocity ﬁeld within the cleft
BIOMEDICAL
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can be examined and this 2-D velocity ﬁeld used in the
transport equation for the solute concentration.
We ﬁrst examine the results of this 2-D model for
Michel and Phillips steady state experiments in Fig. 2
for two cases, Pc = 43 cm H2O, a high ﬁltration state,
and Pc = 15 cm H2O, a value signiﬁcantly below
plasma oncotic pressure, Figs. 4 and 5 respectively.
There is a small negative swelling pressure in the tissue
of  2 mmHg.68 In Fig. 4a we see that at the high
pressure, 43 cm H2O, nearly half of the pressure drop
occurs across the GCX and there is a signiﬁcant
additional drop in pressure as the water is funneled
into the break in the junction strand. The pressure
drop across the junction strand at x = 200 nm is
nearly the same as the pressure drop across the GCX.
The breadth of the spread in pressure on the GCX side
of the break is wider than on the tissue side leading to a
narrower water jet on the exit side than the entrance
side (velocity proﬁles not shown). More striking in
Fig. 4b is the fact that the concentration proﬁle behind
the GCX at x = 0 is nearly identical to that at the cleft
exit. The albumin diffusion coefﬁcient in the cleft is
assumed to be that of free diffusion D¥ whereas that in
the GCX DG is 1000 times smaller. This value of DG
provides for a very close ﬁt of the bend in the curve
shown in Fig. 2 for Michel and Phillips steady state
experiments. This observation, that the concentration
in the cleft is nearly uniform, is central to Michel’s133
simpliﬁed one-dimensional model. Note also that in
this high ﬁltration limit C at the cleft exit has the
limiting value (1  r)CL for pure ﬁltration across the
GCX.
The near uniformity in concentration at the cleft
exit in Fig. 4b may seem surprising since there is a
spike in the velocity proﬁles (not shown to save space)
downstream of the break in the junction strand. The
detailed concentration proﬁles at different y locations
show why this is the case. Along y = 0, the cleft centerline, the concentration does drop continuously
along the cleft centerline from a value 0.07 to near 0.06
close to the convection limit since r = 0.94. One notes
that there is a small but not insigniﬁcant drop in
concentration, roughly 3%, across the junction strand
at larger values of y due to the diffusional spreading in
the y direction. Convection is not important since there
is hardly any ﬂuid motion in the y direction except in
the immediate vicinity of the junction strand breaks.
Michel’s133 model does not consider any mixing processes at the cleft exit but only requires that far from
the cleft exit one has to achieve a uniform concentration Ci = CA = Js/Jv since there is no region B in
Fig. 3. In Weinbaum219 and Hu et al.78 a simple realistic model is developed for this mixing process in region B. The ﬂow at the cleft exit is treated as a line
source whose velocity and concentration vary in the y
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direction and transport equations for the radial and
axial spread of the cleft exit jets are developed which
satisfy appropriate matching conditions with the twodimensional solutions in the cleft.
In Fig. 5a we see the steady state pressure distribution for the case where Pc = 15 cm H2O and a small
negative tissue pressure of  2 mmHg due to tissue
matrix expansion. The pressure proﬁles behind the
GCX at x = 0 and the cleft exit x = 0 differ only
slightly indicating that that there is hardly any water
ﬂux in the cleft except for a very low ﬁltration since the
pressure at x = 0 is slightly higher than the cleft exit.
The concentration proﬁles in Fig. 5b look very similar
to those for PC = 43 cm H20 in Fig. 4b with the
important exception that the dimensionless cleft exit
concentration at x = 400 nm is now close to 0.32. The
drop in concentration across the junction strand more
distant from the junction strand breaks is again about
3%. Since the experiment starts with the tissue side in
pure Ringer solution it is evident that the transition to
steady state, which takes several minutes, occurs
through a process where initially after the rapid drop
in pressure from 43 cmH2O to 15 cm H2O there is
reabsorption which brings water into cleft where the
GCX acts as a molecular sieve causing the protein
concentration behind the GCX to increase until there
is a near equilibrium of hydrostatic and oncotic pressures across the GCX. This is clearly seen in Fig. 5c
where the concentration across the cleft is shown when
this equilibrium is achieved. One notes that along the
center line of the junction strand break there is a small
positive gradient directed toward x = 0. In the plasma
the sum of the COP 26 cm H2O and hydrostatic
pressures 15 cm H2O is a net 9 cm H2O whereas behind the GCX at x = 0 the average oncotic pressure is
roughly 0.34 pp or 9.5 cm H2O providing for a very
small ﬁltration through the junction strand breaks.
In summary, the steady state solutions at
Pc = 43 cm H2O and Pc = 15 cm H2O in Figs. 4 and
5 show that concentration gradients behind the GCX
within the cleft are very small because the diffusional
resistance in the GCX overwhelms that in the cleft itself and at the low ﬁltration pressure a steady state
reabsorption cannot be achieved because the back ﬂow
from the tissue will cause the concentration behind the
GCX to rise to a value that is nearly equal to that in
the lumen and a very low level of positive ﬁltration is
achieved.
Why Does Michel’s 1-D Model Work?
The results in Figs. 4 and 5 raise the critical question. Why does the simple one-dimensional model
proposed in Michel133 provide such good agreement in
the steady state data in Fig. 2 when it neither describes

The Glycocalyx and Its Role in Vascular Physiology and Vascular Related Diseases

the transport in the cleft or the mixing at the cleft exit?
The answer to this is that the model contains one degree of freedom, the permeability coefﬁcient Ps that
appears in the Peclet number Pe = (Jv/A)(1  r)/Ps in
Michel’s equation


Jv
ð1  ePe Þ
2
¼ Lp DP  r pp
:
ð3Þ
A
ð1  rePe Þ
By choosing the desired value of Ps or Peclet number Pe one can obtain an optimum ﬁt for the steady
state curve in Fig. 2. In essence this one parameter
captures the combined resistance of the GCX, the cleft
and the mixing region B in Fig. 3 of the two-dimensional model in Weinbaum219 and Hu et al.78
What Happens If the Tissue is Back Loaded or There is
a Vesicular Pathway?
While Michel’s transient and steady state experiments in Fig. 2 are very insightful they were performed

FIGURE 6. Predictions of theoretical model for Pc = 43 cm
H2O for concentration profiles in the cleft along x (a) and
along y (b) when there is a parallel non-convective pathway
for albumin which increases the tissue concentration at the
edge of region B, Ca, to 0.4Cc. Flow geometry is shown in
Fig. 3. Plasma oncotic pressure is 26 cm H2O and r = 0.94.
Reprinted from Ref. 78.

in only one species, frog, and in one tissue, mesentery.
In marked contrast the in vivo results in Levick,107
where the classic Starling principle was being challenged, included skin, muscle and lung tissue in
humans and several animal species. For many of these
tissues the solute concentration in the far ﬁeld in region
C in Fig. 3 is typically 0.4 CL. The solutions for the
concentration proﬁles within the cleft for this case are
shown in Fig. 6a and 6b. While the cleft and junction
strand geometry is typical of frog mesenteric venules,
the only available cleft geometry at the time, subsequent detailed reconstructions of rat mesenteric venules by Adamson et al.1 revealed a quite similar
structure. The results in Fig. 6a and 6b are for a high
ﬁltration state where PL = 43 cm H2O.
The results in Fig. 6a differ greatly from the concentration proﬁles in Fig. 4b where at the same lumen
pressure the concentration is nearly uniform throughout the cleft and satisﬁes the convective limit
(1  r)CL. The basic difference is that all the solute
passes through the breaks in the junction strand in
Fig. 4b whereas in the present case there is another
transendothelial pathway for large solutes which is
non-convective, e.g. vesicular transport. There is a
large increase in concentration across the junction
strand and the concentration at the cleft exit is close to
0.4 CL except in the vicinity of the junction strand
break. Here the convective ﬂow through the break
greatly impedes back diffusion from the tissue into the
protected region between the GCX and the front part
of the junction strand. Because of the large difference
in concentration across the junction strand the concentration behind the GCX can differ greatly from that
in the tissue and the classical Starling Eq. (1) no longer
applies.
These results are more easily understood if one
looks at the concentration proﬁles in Fig. 6b at ﬁxed
values of y from x = 0 to the far ﬁeld at x = 5 lm,
the edge of region B where the concentration is 0.4 CL.
For values of y removed from the junction strand
break the concentration behind the GCX is uncoupled
from that in the tissue and on the centerline of the
break, y = 0, where the C proﬁle is continuous, the
dimensionless concentration increases from 0.08 at
x = 0 to 0.18 at the cleft exit. This same behavior will
be observed if the tissue is back loaded as we discuss
next.
The behavior just described was convincingly
demonstrated in both frog77 and rat mesenteric
venules1 where the tissue was back loaded so that the
lumen and tissue concentration were both 50 mg/mL.
In addition, serial section microscopy was performed
to determine the location and spacing of the junction
strand breaks so that the 2D model in Weinbaum219
could be rigorously applied. In both experiments the
BIOMEDICAL
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FIGURE 7. Fluid exchange in single rat mesenteric venules
at controlled microvascular pressure, measured by the
modified Landis red cell method (transient state). The lumen
was perfused with albumin solution and the exterior was
superfused with saline (‘no tissue albumin’, open symbols) or
the same albumin solution as in the lumen (‘tissue albumin’,
filled symbols). Short dashes show the expected increase in
filtration rate for the latter according to the classic Starling
principle. The much smaller observed response was as
predicted by the glycocalyx–cleft model. Reprinted from Ref.
108.

lumen was perfused with albumin and the exterior of
the mesentery was superfused with saline or the same
albumin solution as in the lumen. The experiments for
rat mesentery are shown in Fig. 7.
The short dashed curved represents the classical
Starling prediction when pL = pi. The longer dashed
curve represents the results with tissue albumin at the
same concentration as the lumen. For frog mesentery77
there was very little change in the ﬁltration rate in
marked contrast to the classical Starling prediction but
in good agreement with the two-dimensional Weinbaum model in Hu et al.78 In the reﬁned series of
experiments with rat mesenteric venules shown in
Fig. 7 (Fig. 4b in Levick and Michel108) the increase in
Jv due to raising pi from zero to plasma level, was only
30% of that predicted by the classic Starling equation.
Measurement of ﬁltration across conﬂuent cultured
bovine endothelium in a Ussing chamber where the
oncotic pressure was either the same or different in the
luminal and abluminal reservoirs by Pang and Tarbell160 have given results very similar to those just
described. At the time these tissue culture experiments
were performed the role of heparinase in compromising the GCX had not been performed.
Pericytes and Enclosed Microdomains
We close this section with what is probably the most
important mystery in the Michel and Phillips135 paper,
the time scale over which the transition from the
transient to the steady curves in Fig. 2 occurs. This
transition was completed in a time that was typically
less than 2 min. Using the simpliﬁed 1D model in
BIOMEDICAL
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FIGURE 8. Electron microscope images of a rat venular
microvessel (VM). (a) Cross-section of a VM in rat
mesentery. There are seven endothelial cell (EC) clefts, C1–
C7, with all of the cleft exits covered by neighboring pericytes
(PCs). PCs are immediately underneath ECs. There are two
fibroblasts (fib.) outside PCs. The blowout shows C2 covered
by a PC with a trapped microdomain (TM) of uniform
thickness in between. (b) An enlarged view showing a cleft
exit covered by a PC, creating a TM of roughly uniform
thickness except at the narrow exit. Reprinted from Ref. 242.

Zhang et al.,241 one can estimate both Jv/A and JS and
calculate how long it would take the tissue concentration Ci to change. The velocity in the transient state
at the cleft exit when the pressure is dropped from 43
to 15 cm H2O at the start of reabsorption is  5.6 lm/
s and slowly rises to 0.2 lm/s when the new steady
state of low ﬁltrations is achieved (see Fig. 1 in Zhang
et al.242). There is a 500 fold expansion in area from the
cleft exit to the surrounding tissue so the average
velocity in the tissue surrounding the cleft exit is
roughly 0.002 times the cleft exit velocity or ~ 6 nm/s.
The tissue itself is ﬁlled with water that has entered
during the high ﬁltration state and its concentration is
close to the convective limit which we showed in Fig. 4
is 0.07CL. The half spacing of the mesenteric venules is
typically 100 lm and it is this tissue volume which
needs to be drained to achieve the new steady state of
slow ﬁltration. Using the above estimate of the water
velocity in the tissue this would take approximately 5 h
and not two minutes and yet the concentration in the
cleft has risen from 0.07 CL to 0.32 CL at the cleft exit.
A similar calculation for the solute would show that it
would take 6 days for the solute ﬂux from the cleft to
raise the tissue concentration from 3 to 25.6 mg/mL.
This is impossible unless something fundamental has
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FIGURE 9. Time-dependent change in v, C, and w at the cleft exit. Velocity v (a) and concentration C (b Left) and thickness w of
region TM (b right) as functions of time after PL is dropped from 60 to 15 cm H2O. Reprinted from Ref. 242.

been left out of the analysis. This basic paradox was
ﬁnally explained in Zhang et al.242
In the same way that there is a small protected region or enclosed microdomain between the rear of the
GCX and the front of the tight junction strand, there is
a similar enclosed microdomain at the cleft exits of rat
mesenteric venules as shown in Fig. 8. These venules
which are typically about 40 lm in diameter have
typically 7–8 cleft exits along a vessel cross-section. Approximately 85% of these cleft exits are covered by pericytes (PC) which cover much of the surface
of these venules. As shown in the enlarged image in
Fig. 8b there is an enclosed trapped microdomain
(TM) formed by the pericytes surrounding the cleft
exits whose thickness can vary between 100 and
500 nm depending on the state of hydration. At the
edge of the TM there is an attachment region or adherens junction between the EC membrane and the
edge of the PCs. The TM region is very similar in
structure to the region between the EC layer in aortic
endothelium and the internal elastic lamina which also
has been shown to vary in thickness by about ﬁvefold
depending on the pressure in the lumen and state of
hydration.80,81
Zhang et al.242 have developed an elastohydrodynamic model for the TM region observed in Fig. 8. The
key results in this model are shown in Fig. 9a and 9b.
One observes in Fig. 9a how the ﬂuid drains from the
TM in the case when PL has been quickly dropped
from 60 cmH2O to 15 cmH2O and a new steady state
allowed to develop. One notes for this case that the
cleft exit velocity increases from  7.4 lm/s reabsorption to 0.2 lm/s, a slow rate of steady ﬁltration. In
Fig. 9b we see how the concentration in the TM
increases from 3 mg/mL to 25.6 mg/mL as the ﬂuid
drains out of the TM and the change in TM thickness
W from 500 nm to roughly 100 nm due to this ﬂuid
reabsorption. The key observation is that the time scale

of this transition process is typically one minute, very
similar to the classic paper of Michel and Phillips,135
and not hours. The experiments in Michel’s paper were
conducted in frog mesenteric venules whereas the
model results in Fig. 9 were based on the rat mesenteric venules shown in Fig. 8.
The model just described applies to tissues where a
large fraction of the EC clefts are covered by pericytes
and ﬁltration occurs primarily through the clefts.
However, the model can also be applied to skeletal
muscle if there are small regions where water can
accumulate. Clinically it has been observed that reabsorption can continue in human skeletal muscle for 20–
30 min after a sudden drop in PL as would occur after
hemorrhage.107 Typical reabsorption when PL was
reduced 5 mmHg was 15–30 mL per kg of tissue in
30 min. Thus, reabsorption of between 0.3 and 0.6 L is
expected from 20 kg of human muscle in 20–30 min.
This reabsorption would produce a 15–20% increase in
interstitial concentration. This is enough to slow but
not stop further reabsorption and is shorter than values of an hour or more that would be required to
produce changes in the total ISF volume.
In summary, we have tried to highlight in this section the fundamental diﬀerences between the one-dimensional model in Michel133 and the two-dimensional
model in Weinbaum219 and Hu et al.78 where the detailed effect of the cleft and its junction strand can be
examined as well as the mixing process at the cleft exit.
We have also tried to explain why Michel’s one-dimensional model works so well in ﬁtting the steady
state results in Michel and Phillips135 in Fig. 2. The
mixing process at the cleft exit is of particular signiﬁcance when the tissue concentration is raised by a nonconvective parallel pathway. We also explored the role
that pericytes at the cleft exit play in determining the
time scale of the transition from transient to steady
state behavior, as might occur in muscle tissue when
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there is a sudden drop in capillary pressure due to
hemorrhage, if there are local regions of trapped water
in the vicinity of the microvessels.
This opening section of Part A, on the revised
Starling Principle, has begun to reveal how vascular
physiology is inﬂuenced by the GCX. This theme
continues in the next section on Mechanotransduction
with its emphasis on the GCX as a mechanosensor for
shear-induced nitric oxide production and substrate
stiﬀness-induced endothelial dysfunction associated
with loss of GCX. The ﬁnal section of Part A describes
new insights into GCX structure obtained through
high resolution microscopy that will contribute to future advances in cardiovascular physiology.
Mechanotransduction
An important physiological function of the GCX is
to serve as a mechanosensor and transducer.61,69,200–202,220 It is well known that a dysfunctional endothelium is an early manifestation of
atherosclerosis234 and that in disease prone locations
such as branches and curvatures, the ﬂow departs from
pulsatile, unidirectional shear stress to create ﬂow
separation zones that include low wall shear stress,
ﬂow reversal, oscillatory and multi-directional shear
stress, and sometimes turbulence (chaotic ﬂow).39,41,247
In contrast, in adjacent, non-diseased regions, shear
stress is higher and ﬂow is unidirectional with minimal
reversal. The GCX plays an important role in EC
mechanotransduction of shear stress that mediates
localization of atherosclerosis. Weinbaum et al.221
pointed out that the existence of the GCX could reduce
the ﬂuid shear stress on the vascular EC surface to a
negligible level, while Secomb et al.185 described the
transfer of ﬂuid mechanical shear stress at the interface
between the ﬂuid and the outer regions of the GCX, to
solid mechanical stress within the matrix that is
transmitted to the cell body. Thi et al.205 further
showed that the GCX is required for the EC
cytoskeleton to respond to shear stress.
It is well established that after 24 h of laminar ﬂow,
ECs align in the direction of ﬂow and their proliferation is suppressed. Yao et al.229 removed HS from EC
in vitro using the speciﬁc enzyme heparinase III and
observed that EC no longer aligned under ﬂow after
24 h and they proliferated as if there were no ﬂow
present. Subsequently, Baeyens et al.7 reported that EC
in the thoracic aortas of syndecan 4 (SDC4) null mice
were poorly aligned in the direction of the ﬂow. They
found that depletion of SDC4 in human umbilical vein
ECs (HUVECs) using shRNA also inhibited ﬂow-induced alignment in vitro, which was rescued by re-expression. In hypercholesterolemic mice, they observed
that deletion of SDC4 drastically increased
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atherosclerotic plaque burden with the appearance of
plaque in normally resistant locations.
Shear-Induced Nitric Oxide Production
Eﬀects of Enzyme Degradation of GCX on NO Production
Florian et al.60 showed that enzymatic removal of
HS from the surface of cultured EC in vitro with
heparinase III completely blocked shear-induced NO
production in both steady ﬂow (15 dyn/cm2) and
reversing oscillatory ﬂow (10 ± 15 dyn/cm2) out to 3 h
exposure. These experiments included both the early
phase (seconds to minutes after a step increase in
shear) that is calcium and G-protein dependent as well
as the later phase (minutes to hours) that is independent of calcium and G-protein.98 Yen et al.231 later
demonstrated in vivo that degradation of HS in the
GCX of rat mesenteric microvessels greatly inhibited
NO production in response to an increase in ﬂow.
Pahakis et al.159 showed that shear-induced NO production was blocked by enzymes removing HS and
HA, but not CS and that these treatments had no effect
on the shear-induced production of the important
vasodilator and antiplatelet agent, prostacyclin (PGI2).
In related work, Dull et al.48 examined the transmural pressure vs. hydraulic conductivity (Lp) relationship in lung microvascular ECs and demonstrated
that HS participates in pressure-sensitive mechanotransduction that results in EC transport barrier
dysfunction. Note that increased transmural pressure
drives increased ﬂow through intercellular junctions
and over the nearby EC surfaces. Pretreatment of lung
capillary EC with heparinase III completely abolished
the pressure-induced increase in Lp and reduced
intracellular NO detected by a ﬂuorescent dye, suggesting that cell-surface HS directly participates in
mechanotransduction resulting in NO production and
increased Lp. In a related in vivo study Dull et al.47
examined the roles of HS and NO in pressure induced
alterations of the capillary ﬁltration coefﬁcient, K(fc),
and found that heparinase III attenuated the effects of
increased capillary pressure on K(fc).
GCX Core Proteins Involved in NO Production
Because the proteoglycan core protein glypican-1
(GPC1) only binds HS and not CS and the dominant
apical syndecan (syndecan-1; SDC1) binds both HS
and CS, it was hypothesized that GPC1 is the core
protein that transmits the ﬂuid shear force sensed by
the HS to the cell surface where it is ultimately transduced via the phosphorylation of endothelial nitric
oxide synthase (eNOS) into NO. This hypothesis was
tested by Ebong et al.50 who showed that knockdown
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of GPC1 using shRNA completely blocked shear-induced phosphorylation of eNOS, whereas knockdown
of SDC1 had no effect. Because knockdown of genes
by shRNA can have off-target effects, the hypothesis
was further tested using atomic force microscopy
(AFM) with cantilevers coated with speciﬁc antibodies
to HS, GPC1, and SDC1.12 Force applied to HS or
GPC1 resulted in NO production, whereas force
applied to SDC1 did not. These experiments were
carried out at 10 and 30 min and did not speciﬁcally
interrogate the early G-protein-dependent phase of
activation. Zeng and Liu237 found that shear stress has
a dual role in eNOS activation: 4 dyn/cm2 shear stress
inhibited the activation of eNOS, and 15 dyn/cm2
shear stress induced it. Removal of GPC1 by phosphatidylinositol phospholipase C (PI-PLC) signiﬁcantly suppressed the shear stress-induced eNOS
activity at 15 dyn/cm2 shear and further reduced the 4
dyn/cm2-inhibited eNOS activity.237
Glypican-1 and PECAM-1 Interact in NO Production
Recent work has shown that ECs transfected with
platelet endothelial cell adhesion molecule-1 (PECAM1) siRNA lose their inherent sensitivity to ﬂow in the
production of NO.59,226 In both bovine aortic ECs
(BAECs) and HUVECs, the absence of PECAM-1
protein decreased the phosphorylation of eNOS at
ser1177 and production of NO after 30 min of
ﬂow.59,226 Xu et al.226 found that ﬂow-mediated eNOS
phosphorylation in vivo induced by voluntary wheel
running was reduced in PECAM-1 knockout mice.
These ﬁndings implicate PECAM-1 as an important
regulator of shear-induced NO release in ECs, although they do not clarify whether PECAM-1 directly
senses ﬂow to initiate these processes or responds to an
upstream sensor of ﬂuid shear stress.
In many cases, PECAM-1 works in conjunction
with other mechanisms to sense changes in extracellular ﬂuid ﬂow.43,125,208 HS and GPC1 cluster via
mobile lipid rafts at cell–cell junctions, where the
majority of PECAM-1 is located, after 30 min of ﬂuid
shear stress application.239 A HS-to-PECAM-1 binding complex has been shown to exist29,33 and participate in early phase endothelial mechanotransduction.43
Human coronary artery ECs (HCAECs) treated with
heparinase III or reconstituted with PECAM-1 mutants lacking HS binding domains had inhibited (early
phase) shear-induced signaling, speciﬁcally Akt phosphorylation.43
In addition to forming binding complexes with its
extracellular Ig-like domains, PECAM-1 can also
participate in signaling cascades by activation of its
intracellular tail. PECAM-1 has two highly conserved
tyrosines, 686 and 663, that become phosphorylated in

response to mechanical force, including physiologic
levels of ﬂuid shear stress in ECs.125,157 PECAM-1
phosphorylation is mediated by Src family kinases,
speciﬁcally c-Src.59,125,157 PECAM-1 activation is also
regulated by recruitment of the protein tyrosine
phosphatase SHP-2, which dephosphorylates PECAM-1, allowing cyclic signaling waves to stem from
continuous ﬂuid shear stress application.79,125 Importantly, blocking PECAM-1 phosphorylation using the
Src kinase inhibitor PP1 completely blocks downstream shear-induced eNOS phosphorylation,59 clarifying that PECAM-1 activation is a critical step in
shear-induced NO production via the phosphorylation
of eNOS.
Recently, Zeng et al.240 described the relationship
between GPC1 and PECAM-1 in shear-induced production of NO. Using AFM methods on HUVECs and
rat fat pad ECs (RFPECs) in vitro for 30 min, they
showed that force applied directly to GPC1 induces
NO production while force applied directly to PECAM-1 does not. When PECAM-1 was knocked down
by siRNA, force applied directly to GPC1 did not induce NO production. Furthermore, using GPC1
knockout mice, Bartosch (unpublished data) demonstrated lower NO production than the wild type mice
under chronic ﬂow conditions with no differences in
PECAM-1 expression. Under acutely increased ﬂow
stimulated by administration of dobutamine that elevates heart rate, there was an upregulation of NO
production in the wild type mice after 30 min, but no
increase in the knockout mice. These results demonstrate that GPC1 is the upstream shear sensor and
PECAM-1 is the downstream effector.
But how does GPC1 communicate with PECAM-1?
In Zeng et al.240 it was shown that blocking interactions between the HS GAG on GPC1 and the extracellular domain of PECAM-1 had no effect on
signaling, while enzymatic removal of HS from GPC1
blocked phosphorylation of the intracellular domain of
PECAM-1 and downstream phosphorylation of
eNOS, the precursor to NO formation. The overall
mechanism suggested by these studies is summarized in
Fig. 10.
Shear-Induced PGI2 is Mediated by PECAM-1
To follow-up on the observation that GAG removal
by enzymes did not block shear induced PGI2 production,159 Russell-Puleri et al.176 investigated primary
cilia, SDC4, and PECAM-1, as potential
mechanosensors for PGI2 production. Primary cilia are
localized to the apical surface of EC and SDC4 to the
basal surface. In conﬂuent ECs PECAM-1 localizes at
intercellular junctions where it regulates homophilic
binding between cells. Separate knockdown of the
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FIGURE 10. Shear-Induced Nitric Oxide Production via Heparan Sulfate and Glypican-1 Mechanotransduction and PECAM-1
Phosphorylation leading to eNOS activation and NO synthesis. Fluid shear stress is initially sensed by heparan sulfate
proteoglycan glypican-1. That signal is transduced to the intracellular tail of PECAM-1 protein. PECAM-1 becomes activated by
tyrosine phosphorylation. PECAM-1 activation triggers phosphorylation of eNOS and NO production increases. Reprinted from
Ref. 240.

FIGURE 11. Substrate stiffness inhibits the glycocalyx GAG heparan sulfate. HUVECs were cultured on polyacrylamide gels of
stiffness ranging from 2.5 kPa (soft gel) through 10 kPa (stiff gel) up to 100 kPa. Heparan Sulfate (green) expression was assessed
by immunostaining. Cell nuclei were identified using DAPI. Reprinted from Ref. 120.

three putative mechanosensors in cultured cells revealed that only PECAM-1 deletion blocked shearinduced PGI2 production and upregulation of the enzyme cyclooxygenase 2 (COX-2) by a mechanism
involving inside-out activation a5b1 integrin. The role
of PECAM-1 in shear-induced PGI2 was further conﬁrmed in a PECAM-1 knockout mouse model.176
Conway et al.32 using a ﬂuorescence resonance energy
transfer (FRET) tension sensor, showed that shear
stress increased tension across PECAM-1 at intercellular junctions, suggesting a mechanism by which shear
stress activates PECAM-1.
Substrate Stiﬀness Suppresses the Glycocalyx
With increased age, or as a result of hypertension,
arteries lose elasticity and thicken, giving rise to a
stiﬀened arterial wall and substrate for ECs.140,217
Arterial stiffness is a key underlying risk factor for,
and is a hallmark of, age-related cardiovascular diseases such as atherosclerosis and stroke.141 EC dysfunction, characterized by increased proliferation,
permeability, and inﬂammation is at the heart of the
BIOMEDICAL
ENGINEERING
SOCIETY

mechanisms driving these age-mediated vascular diseases. Arterial stiffness is a key trigger for EC dysfunction to occur.49,124
In a recent study, Mahmoud et al.120 showed that
EC grown on polyacrylamide (PA) gels of substrate
stiffness 10 kPa (mimicking the subendothelial stiffness of aged, unhealthy arteries) displayed a signiﬁcant
inhibition of GCX expression compared to cells cultured on softer PA gels (2.5 kPa, mimicking the
subendothelial stiffness of young, healthy arteries).
The effect of stiffness on HS immunostaining is displayed in Fig. 11. Gene and protein screens revealed
that a GCX core protein, GPC1, was inhibited in cells
cultured on stiff gels.
Cells grown on 10 kPa gels had enhanced EC dysfunction as determined by enhanced cell inﬂammation
(enhanced inﬂammatory gene expression, monocyte
adhesion and inhibited eNOS phosphorylation), proliferation and endothelial mesenchymal transition
(EndMT). Removal of GPC1 using gene-speciﬁc
silencing with siRNA or gene overexpression using a
plasmid revealed that GPC1 is required to protect
against stiﬀness-mediated EC dysfunction. Consistent
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with this, using a model of age-mediated stiﬀness, older
mice exhibited a reduced expression of GPC1 and enhanced EC dysfunction compared to young mice. EC
dysfunction was exacerbated in young, but not aged,
GPC1 knockout mice.
Structural Mechanism-Ultrastructure and Organization
of Endothelial GCX
In addition to the above summarized molecular
mechanisms by which GCX plays its role as a mechano-sensor and transducer, an organized structure of
endothelial GCX at the molecular level is necessary.
Due to the limitation of optical and electron microscopy, the ultra-structure of endothelial GCX has not
been revealed until the recent development of
super resolution stochastic optical reconstruction microscopy, STORM.14,225 Fan et al.57 used two photoswitchable dyes, ATTO488 and AF647, to label HS
and HA of GCX on bEnd3 (mouse brain microvas-

cular EC) monolayers, and revealed their organization
and ultra-structure by N-STORM (Fig. 12). Figure 12
demonstrates that HA is a long molecule weaving into
a network which covers the endothelial luminal surface. In contrast, HS is a shorter molecule, perpendicular to the cell surface. HA and HS are partially
overlapped with each other at the endothelial luminal
surface. These ﬁndings suggest that HS plays a major
role in mechanosensing and HA plays a major role in
the molecular sieve.

PART B: THE ROLE OF THE GLYCOCALYX
IN VASCULAR RELATED DISEASES
Infectious Diseases
Since the GCX is at the interface of the circulating
blood and vessel wall, in addition to experiencing the
forces generated by the blood ﬂow, it is constantly

FIGURE 12. Illustrations of STORM images for HS and HA from the cell luminal surface. In the illustrations, the second column is
the HS image (green), the third column is the HA image (red) and the first column is the overlay of the second and the third
columns. The first row is the 2D top view and the second row is the 3D view of the field of ~ 34 lm 3 34 lm. The third and fourth
rows are the enlarged 2D and 3D views from the region with the green dashed line in the first row. The color bar at the left of the 3D
view for HS (second column) and HA (third column) represents the depth (length) scale. Reprinted from Ref. 57.
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aﬀected by the blood-borne substances including toxins from infectious diseases.
Sepsis
Sepsis is a serious medical condition. It is caused by
an overwhelming immune response to infection. The
body releases immune chemicals (cytokines) into the
blood to combat the infection. The cytokines trigger
widespread inﬂammation, which leads to blood clots
and leaky blood vessels. As a result, blood ﬂow is
impaired, and that deprives organs of nutrients and
oxygen and leads to organ damage. In severe cases, one
or more organs fail. In the worst cases, blood pressure
drops, the heart weakens, and the patient spirals toward septic shock. Once this happens, multiple organs,
lungs, kidneys, brain, may quickly fail, and the patient
can die. Sepsis is a major challenge in hospitals, where
it is one of the leading causes of death. It aﬄicts >
750,000 individuals annually in the United States
alone and has mortality rates of 40–60%.63
Sepsis occurs unpredictably and can progress rapidly. Many types of microbes can cause sepsis,
including bacteria, fungi, and viruses. However, bacteria are the most common cause. One of the key
molecular causes of Gram-negative bacteria induced
septicemia is endotoxin that consists of lipopolysaccharides (LPSs) bound with high aﬃnity to LPSbinding glycoprotein. Complex LPS-binding glycoprotein is recognized by cognate receptor Toll-like
receptor 4 (TLR4) and co-receptor CD14 on monocytes/macrophages and ECs to induce the secretion of
proinﬂammatory cytokines.3 Considering the systemic
nature of septicemia, vascular endothelium represents
the ﬁrst line of exposure to bacterial endotoxins. The

role of microcirculation and microvascular endothelium in the pathogenesis of septic multiorgan failure
has been known for a long time,3 but recent studies
have identiﬁed endothelial GCX in manifestations of
endothelial dysfunction in sepsis.182,194,248
Among the earliest responses of activated ECs to
endotoxin are exocytosis of Weibel-Palade bodies
(WPBs) and secretory lysosomes. WPBs are rodshaped members of lysosome-related organelles
(0.2 lm by 2 to 3 lm) characteristic to ECs and containing an array of proteins, peptides and cytokines,
which can be released quickly on urgent demand. The
endothelial lysosomes contain acid/secretory sphingomyelinase, glycohydrolases, cathepsins, fucosidase,
phosphatases, HS sulfatase, among others. Some of
these enzymes can degrade the endothelial GCX. Upon
application of LPS for minutes to simulate the onset of
sepsis, confocal and STORM microscopy conﬁrmed
the patch loss of GCX simultaneously with the exocytosis of lysosome-related organelles and WPBs in
cultured ECs and mouse aorta248 (Fig. 13). During
sepsis, the GCX becomes thinner, inducing tissue
edema.25,209 In mice, intravenous LPS injection results
in elevated levels of tumor necrosis factor (TNF)-a and
IL-6.58 Elevated levels of TNF-a contribute to GCX
damage via increased matrix metalloproteinase (MMP)
activity and syndecan loss.173 In human, low-dose
endotoxin resulted in a signiﬁcant reduction in the
depth of the sublingual vessel GCX and a concurrent
elevation in plasma HA, suggesting GCX shedding.151
Circulating levels of HA and HS have also been
increased fourfold in patients with sepsis, being higher
in those who did not survive 90 days.149 Therefore,
multiple circulating biomarkers of GCX shedding have

FIGURE 13. Representative STORM-acquired images of anti-HS labeled EG and vWF-labeled WPBs distribution in control and
10 min post-LPS. The left panel shows 2D images of a region of ~ 40 lm x 40 lm at the apical surface of cultured mouse brain
microvascular endothelial cell (EC). An enlarged top view of a yellow box (~ 2 lm x 2 lm) in the left panel is shown in the middle
panel and its side view in the right panel. The EC surface is at the bottom of the side view. Upper panels are for the control and
bottom ones for after 10 min LPS treatment. Reprinted from Ref. 248.
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been studied in humans as markers of sepsis, including
SDC1, HS and HA.15,36,118,227
Sepsis, in general, can be characterized as a catabolic state of degradation of proteins, lipids and carbohydrates.215 Recent advanced metabolic gene
expression analysis of LPS-induced endothelial dysfunction found an increase in glycan production to
accompany GCX loss in ECs and an increase in
endothelial permeability.129 Findings in patients with
sepsis showed that upregulation of glycan synthesis
was among the worst-affected areas of metabolism,
being most severe in non-survivors. These observations
are consistent with a view of compensatory induction
of synthesis of structural components of GCX, upon
application of GCX-degrading stressors such as LPS,
suggesting a tight feedback control mechanism coupling its synthesis and degradation. That the degradation of GCX in sepsis prevails over increased
synthesis of glycans, major components of GCX,
suggests an enhanced enzymatic degradation, which is
carried out by sheddases, including a disintegrin and
metalloproteinases (ADAMs), MMPs, heparanases
and hyaluronidases.63 While ADAM 10 is expressed
constitutively, ADAM 17 is inducible, as it is converted to an active form upon cell stimulations.137 In
addition to turning TNF-a into a soluble form,
ADAM 17 cleaves SDC4 while ADAM 10 sheds SDC1
and ADAM15 cleaves CD44.227 MMPs induced in
sepsis activate TNF-a, interfere in CD44-HA binding
and shed HS, CS, and the SDC1 ectodomain.244
The wall of the cerebral microvessel is named the
blood–brain barrier (BBB) which is formed by ECs,
pericytes, basement membrane and astrocyte foot
processes. The GCX on ECs is the most luminal layer
of the BBB. During sepsis, patients develop cognitive
impairment. Although the pathogenesis of this condition is complicated, current studies suggest a role for
cytokines (IL-1, IL-6 and TNF-a) penetrating the BBB
and activating astrocytes.165 Studies also suggest that
during sepsis HS fragments penetrate the BBB in the
hippocampus to inhibit long-term potentiation, the
process responsible for memory formation.76
Increased pulmonary vascular permeability occurs
early in sepsis128 and may be due to GCX damage.
Although a study using bovine lung microvascular ECs
in vitro suggested that HS of GCX contributed to the
barrier function, a study using ex vivo rat lungs did
not.47,48 One explanation for this discrepancy is that
the enzyme degrading HS completely compromised the
barrier function of GCX for the in vitro lung
microvascular ECs formed monolayer, but only partially compromised that of GCX in the ex vivo rat lung
microvessels. In addition to HS, there is signiﬁcant HA
in the GCX of microvessels. As predicated by a
transport model for the paracellular pathway (inter-

endothelial cleft) of the microvessel wall,21 as long as
there is 50% GCX left that covers the inter-endothelial
cleft, the hydraulic conductivity and permeability to a
large sized molecule would not have a signiﬁcant increase. For a rat mesenteric microvessel, the inter-endothelial cleft occupies about 0.2% of a vessel lumen
area.1 Even though 99.8% GCX is degraded from the
vessel lumen, as long as 0.2% GCX still covers the
inter-endothelial cleft, no signiﬁcant increase in the
vascular permeability would be observed. This explanation also applies to the recent ﬁnding by Guerci
et al.64 that GCX degradation is independent of vascular barrier permeability increases in nontraumatic
hemorrhagic shock in rats.
However, if that 0.2% GCX covering the inter-endothelial cleft is damaged, vascular permeability will
be enhanced. If other structural components, such as
tight and adherens junctions inside the inter-endothelial cleft and the width of the cleft are disrupted, large
increases in the vascular permeability will occur. For
example, a study by Schmidt et al.182 shows that immune cell extravasation and inﬂammation during
sepsis can alter the pulmonary GCX, resulting in pulmonary edema.
Using in vivo multiphoton microscopy in mice,
Butler et al.20 observed a continuous GCX (identiﬁed
by ﬂuorescently labeled wheat germ agglutinin bound
to sialic acid) at glomerular capillaries that contributes
to the restriction of macromolecules and water passage
from the glomerulus into the Bowman space. In a rat
model, sepsis at its initial phase alters glomerular GCX
and induces albuminuria (albumin leakage into
urine).2 Taking these together, sepsis ﬁrst destroys the
frontline of the vascular barrier, the GCX, eventually
resulting in multiorgan failure including brain, lungs
and kidneys, to name a few.
Dengue Virus
Dengue is the most prevalent arboviral disease in
humans and a major public health problem worldwide.
Systemic plasma leakage, leading to hypovolemic
shock and potentially fatal complications, is a critical
determinant of dengue severity. A novel pathogenic
eﬀect of the secreted dengue virus (DENV) nonstructural protein 1 (NS1) is triggering hyper-permeability of human ECs in vitro and systemic vascular
leakage in vivo. It has been demonstrated that DENV
NS1 disrupts the GCX on human pulmonary
microvascular ECs, inducing degradation of sialic acid
and shedding of HS proteoglycans by a mechanism
involving NS1-induced expression of sialidases and
heparanase.168 The data suggest an important role for
GCX shedding in Dengue disease.
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In a related study of 103 Dengue-infected patients,
elevated levels of SDC1 and CS were strongly associated with plasma leakage, while elevated levels of
SDC1 and claudin-5 were strongly associated with
severe plasma leakage.196
Flaviviruses
Flaviviruses cause systemic or neurotropic-encephalitic pathology in humans. The ﬂavivirus nonstructural protein 1 (NS1) is a secreted glycoprotein
involved in viral replication, immune evasion, and
vascular leakage during Dengue virus infection. In an
extension of their dengue virus studies, Puerta-Guardo
et al.167 investigated the contribution of secreted NS1
from related ﬂaviviruses and demonstrated that NS1
from Zika, West Nile, Japanese encephalitis, and yellow fever viruses selectively binds to and alters permeability of human ECs from lung, dermis, umbilical
vein, brain, and liver in vitro and causes tissue speciﬁc
vascular leakage in mice, reﬂecting the pathophysiology of each ﬂavivirus. Mechanistically, the observed
hyperpermeability in vitro is related to disruption of
the GCX components sialic acid, HS, and SDC1 following upregulation of sialidases as well as activity and
subsequent expression of heparanase, enzymes known
to contribute to the degradation of cellular GAGs and
proteoglycans in the GCX.196,199
For the common inﬂuenza A virus (IAV) that has
caused the Spanish ﬂu (1918), Asian ﬂu (1957), Hong
Kong ﬂu (1967) and bird ﬂu (2004), multivalent
binding to the host cell surface is a common strategy
for infection. IAV binds to the host cell surface via its
trimeric spike protein hemagglutinin, which recognizes
sialic acids on the GCX of cellular membranes. Despite
the low binding afﬁnity of individual hemagglutinin
receptor binding sites to sialic acid, a stable adhesion
originates from multiple ligand–receptor binding
events between the virus and the sialic acid glycoconjugates on the cell surface.105
Human Corona Viruses
(HCoV-NL63) is an alpha coronavirus that was ﬁrst
identiﬁed in 2004. Previous studies showed that HCoVNL63 and severe acute respiratory syndrome (SARS)CoV (2002) employ the same receptor for host cell
entry, angiotensin converting enzyme 2 (ACE2), but it
is largely unclear whether ACE2 interactions are sufﬁcient to allow HCoV-NL63 binding to cells. Milewska et al.136 showed that directed expression of ACE2
on cells previously resistant to HCoV-NL63 renders
them susceptible, showing that ACE2 protein acts as a
functional receptor and that its expression is required
for infection. However, competition experiments using
a range of soluble elements of cellular membrane-asBIOMEDICAL
ENGINEERING
SOCIETY

FIGURE 14. HSPGs play an important role in the process of
SARS-CoV cell entry. The anchoring sites provided by HSPGs
permit initial contact between SARS-CoV and host cells and
the concentration of virus particles on cell surface. SARS-CoV
rolls onto the cell membrane by binding to HSPGs and scans
for specific entry receptors, which leads to subsequent cell
entry. Reprinted from Ref. 103.

sociated components revealed that HS proteoglycans
(HSPGs) constitute HCoV-NL63 adhesion receptors.
Binding of HCoV-NL63 to heparan sulfates was
required for viral attachment and infection of target
cells.
Lang et al.103 showed that the efﬁcient entry of
SARS-CoV into the infected cells requires the
involvement of HSPGs in concert with ACE2. Increased infectivity of SARS pseudovirus was associated with binding to HS. Elimination of cell-surface
HS by heparinase or the addition of exogenous heparin
reduced the ability of the virus to bind to the cell
surface and increased cellular resistance to infection
(Fig. 14).
In a recent review paper, Sardu et al. 180 emphasized
that to access host cells, SARS-CoV-2 (COVID-19)
uses a surface glycoprotein known as spike to engage
the ACE2 receptor for coronavirus entry. Therefore,
the density of ACE2 in each tissue may correlate with
the severity of the disease in that tissue. ACE2 is
known to be well expressed by ECs. Hypertension,
thrombosis, kidney failure, and diabetes all show
strong co-morbidities with COVID-19 and are known
to be associated with endothelial dysfunction, suggesting that COVID-19 is in a certain sense an
endothelial disease.
Cardiac injury is a prevalent complication in severe
COVID-19 patients, exacerbating the disease severity.
ACE2, the key host cellular receptor of SARS-CoV-2,
has been identiﬁed in multiple organs, and its cellular
distribution in human heart was illuminated recently
by Chen et al.27 They developed a single cell atlas of
adult human heart tissue, and revealed that pericytes
with high expression of ACE2 might act as the target
cardiac cell of SARS-CoV-2. Pericyte injury due to
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virus infection may result in capillary EC dysfunction,
inducing microvascular dysfunction.
Malaria
It has been proposed that a breakdown of the
endothelial GCX plays a key role in severe malaria. In
a study by Introini et al.,85 the interactions between
Plasmodium falciparum infected red blood cells
(PfRBCs) and GCX were investigated in vitro.
Impairment of the GCX was obtained by enzymatic
removal of sialic acid residues, which, due to their
terminal location and net negative charge, are implicated in the initial interactions with contacting cells.
There was a more than two fold increase of PfRBC
adhesion to ECs upon enzymatic treatment, relative to
untreated ECs. As a control, no effect of enzymatic
treatment on healthy red blood cell adhesion was
found. These results provide evidence of the increased
cytoadherence of PfRBCs to GCX impaired vascular
endothelium, thus supporting the role of GCX disruption in the pathogenesis of this disease.
Biochemical assessment of the luminal surface of
ECs from cerebral malaria (CM) mice revealed
malaria-induced loss of SDC1, SDC4, HS and CS.75
This loss was mirrored in increases of the same components in peripheral blood samples. Corticosteroid
treatment protected against CM, reduced inﬂammation, and prevented GCX loss. Adjunctive antithrombin-3 also prevented GCX loss and signiﬁcantly
reduced CM-associated mortality. Thus, GCX loss
may be associated with malaria pathogenesis.
Yeo et al.233 prospectively enrolled Indonesian
inpatients (‡ 18 years old) with severe (SM) or moderately-severe falciparum malaria (MSM) and healthy
controls (HCs). GCX breakdown products were measured in samples of urine and plasma. SDC1 and
GAGs were signiﬁcantly increased in MSM relative to
HC patients and even more so in SM patients. GCX
degradation was positively associated with parasite
biomass in MSM and SM patients and inversely
associated with endothelial NO bioavailability. This
study further supports the view that the GCX is protective against malaria.
Cardiovascular and Related Diseases
Atherosclerosis
Our 2016 review paper200 traced the observations of
diminished vascular GCX in atheroprone locations in
arteries from the study by Lewis et al.109 in the coronary arteries of White Carneau pigeons in the early
1980s, through the study by van den Berg et al.212
20 years later showed that GCX thickness was significantly reduced in the disease-prone sinus region of the

mouse internal carotid artery compared to non-diseased regions in the common carotid artery. Subsequently, van den Berg et al.213 observed that intimal
accumulation of low density lipoprotein (LDL) was
enhanced in the internal carotid branch of mice where
the GCX was thinner than in adjacent regions of the
common carotid. It was suggested that the enhanced
LDL accumulation was due to impaired GCX barrier
properties. In a related study, Nagy et al.148 observed
that inhibition of HA synthesis in a mouse model
facilitated leucocyte adhesion, subsequent inﬂammation and progression of atherosclerosis.
More recently, Cancel et al.22 examined the GCX in
the brachiocephalic artery bifurcation of APOE/
mice fed a high cholesterol diet for 10 weeks and
observed a greatly diminished GCX on the intact ECs
on plaque surfaces of the outer wall compared to the
plaque free opposite wall and plaque-free descending
aorta. The plaque surface was also shown to be a region of elevated EC apoptosis compared to the nonplaque regions. LDL accumulation was enhanced
where the endothelial GCX was thinner and apoptosis
higher than in adjacent regions of the common carotid.
It was suggested that in concert with endothelial
apoptosis that increases lipid permeability, glycocalyx
shedding initiated by inﬂammation facilitates monocyte adhesion and macrophage inﬁltration that promote lipid retention and the development of
atherosclerotic plaques.
Recent studies from H. Jo’s group192 using an
APOE/ mouse model with partial ligation of the left
carotid artery showed rapid development of
atherosclerotic plaques (2 weeks) due to a mechanism
involving oscillatory shear-induced upregulation of
microRNA 712 that suppresses tissue inhibitor of
metalloproteinase 3. This allowed enhanced activity of
MMPs that are known to degrade the GCX.235 We
have previously stained samples from these partial
ligation experiments192 and observed a complete removal of HA in the atherosclerotic vessels.200
Recent ﬁndings indicate that SDC1 is elevated in
serum, indicative of the degradation of GCX, in
patients with ischemic heart disease or heart failure.94
GCX shedding markers have been examined in the
pathophysiology of heart failure with reduced ejection
fraction (HFrEF). HA levels and SDC1 levels were
measured in HFrEF patients. HA was signiﬁcantly
elevated in HFrEF patients and an independent predictor for worse clinical outcome, whereas SDC1 elevation was not signiﬁcant.152
Recent work with 4- to 8-week-old apolipoprotein
E/low-density lipoprotein receptor deﬁcient mice, at
the stage before development of atherosclerotic plaques, displayed increased endothelial stiﬀness, reduced
GCX coverage and thickness, reduced NO production
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in the aorta, impaired acetylcholine-induced vasodilation, and increased endothelial permeability.9 These
observations are consistent with independent studies
reviewed in the sections on mechanotransduction and
sepsis.
Harding et al.,74 using cultured EC in vitro and a
mouse model, have demonstrated that pro-atherosclerotic endothelial dysfunction occurs as a result of disturbed ﬂow-induced reduction in GCX expression and
impaired endothelial sensitivity to ﬂow. Results conﬁrmed that disturbed ﬂow down-regulates caveolin-1
mechanosignaling, as indicated by its reduced colocalization with phosphorylated eNOS (peNOS-serine1177), a vasoregulatory signaling molecule
producing NO that is activated by shear stress through
the GCX. In the absence of HS, uniform ﬂow-conditioned ECs exhibited disturbed ﬂow-like caveolin-1
expression, localization, and colocalization with peNOS.
Stroke
Ueno et al.210 characterized the GCX in capillaries
of the frontal cortex and hypothalamus of strokeprone spontaneously hypertensive (SHRSP) rats. They
observed decreased GCX abundance in the hypothalamus and frontal cortex of SHRSP rats compared to
control Wistar Kyoto (WKY) rats. Similar observations of decreased GCX abundance were made in the
hippocampus of SHRSP compared to WKY rats.210
The GCX is partially accessible to ﬂowing red blood
cells at its luminal side in the so called ‘‘perfused
boundary region’’ (PBR). GCX damage results in
increased PBR, which can be measured in the sublingual microvasculature. Martens et al.94 tested whether
PBR is increased in patients with lacunar stroke, and
further distinguished patients with white matter lesions
as a sign of extensive cerebral small vessel disease.
They observed that white matter lesions are associated
with an increase in the red blood cell permeable part of
the sublingual microvascular GCX, and this implicates
a compromised GCX.
Elevated systemic haematocrit increases the risk of
stroke and myocardial infarction. Richter et al.175 used
an erythropoietin overexpressing transgenic mouse line
(tg6) with a haematocrit of 0.85 to assess the effects of
elevated haematocrit and observed that the GCX is
nearly abolished in tg6 mice. This suggests that the
pathological effects of elevated haematocrit in these
mice, and possibly in polycythemic humans, relates to
a reduced GCX thickness and the consequent alteration in the blood–endothelium interface.
Sehba et al.186 developed a rat model to study the
mechanisms underlying subarachnoid haemorrhage.
This model was used to examine the fate of
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microvascular GCX in the brain 1 h after the imposed
haemorrhage. It was shown that there is a robust GCX
as characterized by HA staining in the control vessels
that is completely degraded in the subarachnoid
haemorrhage model.200
Fihlo et al.206 emphasized that the GCX is an integral constituent of the endothelial barrier, and an
increasing number of studies suggest that recovery and
stabilization of the microcirculation, particularly the
damaged GCX, is a major element of a successful
resuscitation regimen for haemorrhagic shock.207
Chronic Venous Disease
Ligi et al.114 recently reviewed the role of the GCX
in chronic venous disorders underlying common vascular pathologies—varicose veins, edema, venous
ulcerations- of great medical and socioeconomic impact. The predominant pathophysiological mechanisms of chronic venous disease (CVD) start from the
development of venous hypertension and reﬂux, leading to endothelial dysfunction, GCX degradation and
venous wall dilatation. The altered hemodynamics
(disturbed ﬂow) and loss of GCX lead to altered
mechanotransduction upregulating harmful biomolecular pathways, creating a vicious cycle among
shear stress, proteolytic remodeling, and inﬂammatory
processes.
Hypertension and Aging
In our previous review22 we described studies
showing a loss of GCX in the blood–brain barrier of
spontaneously hypertensive rats,210,211 the retinal and
choroidal capillaries of rats with diabetes and hypertension,99 as well as reduced GCX thickness associated
with elevated salt concentration in blood that reduces
the salt sequestering capacity of the GCX leading to
salt overload and hypertension.100,155 It was also
shown that RBCs from hypertensive rats are subject to
enhanced GCX cleavage compared to the RBCs of the
normotensive rats due to the action of blood-borne
MMPs.155
More recently, Schierke et al.181 have shown that
high plasma Na + concentration associated with
hypertension stiffens the endothelial cortex and
diminishes the GCX leading to decreased NO while
inducing endothelial release of pro-inﬂammatory
cytokines promoting monocyte adhesion. Expression
of GCX markers in plasma, including HS, HA, and
SDC1, was detected in monocrotaline-induced pulmonary artery hypertension in rats indicative of
endothelial GCX shedding.66 Endothelial GCX is impaired in untreated hypertensive patients and is related
to arterial stiffness and coronary, and myocardial
dysfunction.84 Preeclampsia related hypertension also
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leads to GCX degradation leading to endothelial dysfunction, reduced microvascular perfusion and vascular injury.222
In a study of the GCX in microvessels of young and
old male mice using intravital microscopy and transmission electron microscopy and in human participants using intravital microscopy, GCX thickness in
mesenteric and skeletal muscle microvessels was 51–
54% lower in old compared with young mice. A 33%
lower GCX thickness in the sublingual microcirculation of humans was observed in advanced age. These
data provide evidence that a diminished GCX is present in advanced age and is accompanied by markers
of impaired microvascular perfusion.119
Alzheimers and Dementia
Nagga et al.147 have demonstrated changes in the
levels of HA in cerebrospinal ﬂuid (CSF) in patients
with Alzheimer’s disease (AD) with documented vascular alterations. To further investigate if the level of
HA in CSF can be used as a clinical diagnostic biomarker to identify vascular pathology, a study of
patients with vascular dementia (VaD) (n = 46), AD
(n = 45), and controls without dementia (n = 26) was
undertaken. They found signiﬁcantly increased levels
of HA in CSF from patients with VaD compared with
controls, whereas the levels of HA in patients with AD
were found to be unaltered compared with controls
and patients with VaD. They also found a signiﬁcant
positive correlation between the levels of HA and the
CSF/serum albumin ratio, an indicator of blood–brain
barrier integrity, in patients with VaD and AD, supporting the role of HA in vascular changes in the brain.
Diabetes
Hyperglycaemia that is linked with diabetes has
been shown in vitro to lead to loss of HS and associated
shear stress-induced phosphorylation of eNOS116 and
elongation of ECs in the direction of shear17 that are
caused by mechanotransduction mediated by HS. In
diabetic individuals, it has been observed that
atherosclerosis is distributed more uniformly in arteries, not following the typical association with regions
of low shear or disturbed ﬂow near bifurcations and
curvatures.40 In addition, vasodilation is altered in
diabetes.174 All of these observations imply a fundamental difference in mechanotransduction by the ECs
of diabetic individuals that may be explained in part by
alterations in the GCX.
Endothelial dysfunction and increased risk for cardiovascular morbidity and mortality are associated
with renal failure. Vlahu et al.216 demonstrated that
dialysis patients shed HA and SDC1 into their blood
and had an impaired GCX barrier. Salmon et al.179

reviewed the role of dysfunction of the GCX in the
glomerulus leading to albuminuria and systemic
increases in microvascular permeability.
Padberg et al.158 examined whether renal failure
correlated with structural changes in the GCX using
nephrectomized rats and patients with chronic kidney
disease (CKD). The physical properties of the GCX
were studied in rats using AFM. The results showed
that CKD is associated with a damaged GCX and that
increased GCX breakdown products correlate with the
physical stability and thickness of the GCX.
Further evidence that HSPGs are shed in diabetes
was provided by Ramnath et al.173 They demonstrated
that the inﬂammatory cytokine TNF-a which induces
disruption of the glomerular GCX in diabetes, reduced
cell surface SDC4 and HS signiﬁcantly. The mechanism involved MMP 9-mediated shedding of SDC4/
HS. In addition, Neves et al.150 evaluated the relationship between plasma SDC1 levels and renal dysfunction in patients with acute decompensated heart
failure. They determined that plasma SDC1 levels
predicted increased risk of developing acute kidney
injury.
Patients with type 1 diabetes present increased
plasma levels of both HA and hyaluronidase 1
(HYAL1) that degrades HA. Dogne et al. 44,45 investigated the role of HYAL1 in the development of
diabetes-induced endothelial dysfunction, endothelialdependent vasodilation, arteriolar GCX size, and
glomerular barrier properties in wild-type and HYAL1
knockout mice with or without streptozotocin (STZ)induced diabetes. Four weeks after STZ injections, the
lack of HYAL1 prevented diabetes-induced increases
in soluble P-selectin concentrations, limited the impact
of the disease on vasorelaxation, increased GCX
thickness, maintained GCX structure and HA content
during diabetes, and prevented diabetes-induced
glomerular barrier dysfunction—all suggesting that
HYAL1 contributes to endothelial and GCX dysfunction induced by diabetes.
Leskova et al.106 investigated the effects of diabetes
and HYAL1 on the thickness of the GCX in the mouse
retina. The retinal circulation of diabetic Ins2 (Akita)
mice and their nondiabetic littermates were observed
via intravital microscopy. In nondiabetic C57BL/6
mice, the GCX thickness also was evaluated prior to
and following infusion of HYAL1. Both diabetes and
hyaluronidase infusion signiﬁcantly reduced the
thickness of the GCX in retinal arterioles (but not in
venules), and hyaluronidase increased retinal
microvascular leakage. The ﬁndings demonstrate that
diabetes and hyaluronidase reduce the thickness of the
retinal GCX, in which HA plays a signiﬁcant role in
barrier function.
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The mechanical properties of the GCX and
endothelium in ex vivo mouse aortas were determined
simultaneously in indentation experiments with AFM
for diabetic and control mice at ages of 11–
19 weeks.203 In diabetic mice, marked endothelial
stiffening and reduced GCX coverage were present
already in 11-week-old mice and persisted in older
animals. In contrast, reduction of GCX length was
progressive and was most pronounced in 19-week-old
diabetic mice. The reduction of GCX length correlated
with an increasing level of glycated haemoglobin and
decreased endothelial NO production secondary to
loss of mechanotransduction through the GCX. The
stiffening of ECs and diminished GCX coverage occurred in early diabetes and were followed by the
reduction of the GCX length that correlated with
diabetes progression.
Exercise and Endurance Training
A recent study evaluated whether oxidative stress
and inﬂammation induced by strenuous exercise aﬀect
GCX integrity and endothelial function in healthy
young men. No signiﬁcant changes in serum SDC1 and
HS concentrations were observed, and it was concluded that a single bout of severe-intensity exercise is
well accommodated by endothelium in young, healthy
men as it neither results in evident GCX disruption nor
in the impairment of NO or prostacyclin production.121 In a follow up study, Majerczak et al.122 found
that moderate-intensity endurance training exerts a
pronounced protective effect on endothelial GCX integrity at rest and during exercise. Training led to a
signiﬁcant decrease in basal and end-exercise concentrations of blood markers of GCX damage (SDC1 and
HS). They suggested this was the result of an
improvement of antioxidant defense that may represent the vasoprotective mechanism highly responsive
to moderate-intensity training.
High-intensity interval training (HIIT) has been
proposed to exert vasculoprotective eﬀects. A study by
Schmitz et al.183 evaluated whether HIIT affects the
microvasculature, including the endothelial GCX barrier. Sidestream dark-ﬁeld imaging was performed at
baseline and follow-up to detect changes of the sublingual microvasculature including the endothelial
GCX thickness. At baseline, a signiﬁcant correlation
between maximal exercise performance capacity and
glycocalyx thickness was detected. Increased exercise
performance at follow-up also correlated with GCX
thickness. Moreover, increased baseline microRNA143 (miR-143) levels predicted increased GCX thickness at follow-up. miR-143 may represent a tool for
monitoring early vasculoprotective adaptations to
physical activity.
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Trauma
Endothelial dysfunction has emerged as a critical
component associated with hemorrhagic shock and
trauma.90 The endothelial GCX is an integral constituent of the endothelial protective barrier, and an
increasing number of studies suggest that recovery and
stabilization of the microcirculation is associated with
GCX recovery.206,207
Johansson et al.90 have reported in trauma patients,
that among the 17 markers of GCX degradation and
endothelial damage, high circulating SDC1 was associated with increased mortality in patients with penetrating injury and severe head injury. Chignalia et al.28
have reviewed the GCX in lung injury and emphasized
that the respiratory epithelial GCX is a target in bacterial pneumonia with emphasis on SDC1 and
hyaluronan.
Cancer (Cancer Cell Glycocalyx)
The cancer cell GCX mediates the interactions
between a tumor and its microenvironment and profoundly aﬀects cancer cell signaling, migration, invasion, and metastasis.18 Paszek et al.163 observed that
circulating tumor cells (CTCs) from patients with
aggressive breast cancers overexpressed bulky glycoproteins. To test whether bulky glycoproteins could
facilitate survival at distant sites, they incorporated a
long glycoprotein mimetic into non-malignant mammary epithelial cells and found cells remained viable
when plated on soft hydrogels that mimic sites of
colonization, whereas untreated cells were not viable.
The bulky GCX promoted growth and survival by
increasing integrin adhesion and signaling. Woods
et al.224 coated tumor cells with synthetic glycopolymers of various thicknesses and found that longer,
bulkier GCX promoted cell survival and proliferation
thus increasing their metastatic potential in a mouse
model.
Altered expression of the GAG components of the
cancer cell GCX, and their cell surface core proteins
and receptors, has long been linked to cancer progression. Increased HA expression is consistently
found in many types of cancers. Increases in tumor cell
associated HA is seen in tumors arising from simple
epithelia such as ovarian, colorectal, and gastric cancer, while increases in HA expression in the tumor
stroma are observed in, for example, breast, prostate,
and bladder carcinomas, and lung adenocarcinomas.
In either case, increased HA expression is associated
with tumor progression and poor survival.198 HA
interactions with its cell surface receptors activate
signaling pathways that modulate cell motility, proliferation, differentiation, and invasiveness.92,139
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CD44 is the major cell surface receptor for HA. Due
to alternative splicing and post-translational modiﬁcations, multiple variants are generated (CD44v).
While the standard form of CD44 (CD44s) is expressed
in most cells, CD44v are expressed in tumor cells and
have been shown to promote tumor progression and
metastatic potential in lung, breast, and colon
cancer.139 Another HA receptor, RHAMM, is upregulated in various cancers and its expression is associated with poor prognosis in lung, breast, colorectal,
gastric, pancreatic, and ovarian cancers.26 The role of
HA-CD44 and HA-RHAMM interactions in cancer
has been reviewed in detail.138
HS interacts with a wide range of growth factors
and chemokines making it essential to many aspects of
cell regulation and function.62 Modiﬁcation of HS by
enzymes such as heparanase, sulf-1, and sulf-2 plays an
important role in regulating cancer growth35 and altered expression of these enzymes is found in many
types of cancers.71,190 Jung et al.91 found that heparanase degrades HS on SDC1 exposing a binding site
that couples vascular endothelial growth factor receptor-2 to a4b1 integrin in multiple myeloma, leading to
tumor cell migration and invasion. Shinyo et al.189
found reduced expression of HS was associated with
the progression of cervical intraepithelial neoplasms to
invasive cancer. Through a different mechanism, HS
on the cancer cell surface mediates ﬂow-induced
migration and metastasis in renal carcinoma cells
(discussed below).169,170 Thus the role of HS in tumor
progression may be context and cell type speciﬁc.
The syndecan and glypican proteoglycans interact,
directly or through their HS chains, with an array of
extracellular matrix proteins that mediate cell-signaling
events during carcinogenesis86 (see Table 1). As with
HS, the role of SDC1 may depend on cell type and

disease stage. Loss of SDC1 appears to be a key step in
regulating epithelial to mesenchymal transition.86 Recently, Kind et al.95 examined tissue microarrays for
SDC1 expression and found it was highest in squamous cell carcinomas such as esophagus, cervix, and
lung and in adenocarcinomas in lung and colorectal
cancer. Expression was low in germ cell tumors, sarcomas, endocrine, and neuroendocrine tumors. Barbareschi et al.10 reported that SDC1 was highly
expressed and associated with aggressive phenotype in
breast carcinoma. By contrast, SDC1 was downregulated in invasive cervical cancer189 and multiple
myeloma.91
Syndecan-2 plays an important role in mediating
cell shape, adhesion and migration.86 Syndecan-2
overexpression is found in low metastatic clones of
Lewis lung carcinoma, and upregulation of syndecan-2
in highly metastatic clones inhibits their metastasis.191
In colon31,162 and breast115 carcinoma cell lines, syndecan-2 promotes tumor progression by mediating cell
adhesion and enhancing migration. Shed syndencan-2
inhibits angiogenesis which affects tumor growth.42
SDC4 is expressed in most tumors and mediates cell
adhesion to the extracellular matrix. SCD4 is downregulated in invasive colon carcinoma,86 but upregulated in the renal cell carcinoma tissue samples.52 The
speciﬁc roles SDC4 plays in tumor progression and
metastasis may depend on cell type and other factors in
the tumor microenvironment86 and more studies are
needed to advance our knowledge in this area.
High levels of GPC1 have been reported in lymphoma,54 breast,126 pancreatic,46,97,117 esophageal,72
and cervical cancer.127 In breast and pancreatic cancer,
GPC1 was shown to modulate the mitogenic response
of cancer cells to heparin-binding growth factors.97,126
GPC1 expression was also a predictor of perineural

TABLE 1. Syndecans and glypicans in cancer.
Component
Syndecans
Syndecan-1
Syndecan-2
Syndecan-4
Glypicans
Glypican-1

Glypican-3

Expression in cancer/possible mechanisms

Upregulated in squamous cell carcinomas, aggressive breast carcinomas; downregulated in
sarcomas, germ cell, and endocrine tumors. Regulates epithelial to mesenchymal transition
Upregulated in highly metastatic Lewis lung carcinoma; promotes tumor progression in breast and
colon carcinomas
Upregulated in renal cell carcinoma; downregulated in invasive colon carcinoma. Mediates cell
adhesion to extracellular matrix
Upregulated in lymphoma, breast, pancreatic, and cervical cancer. Modulates mitogenic response

Upregulated in hepatocellular, gastric, ovarian and lung squamous cell carcinoma; downregulated
in breast, lung, ovary, and mesothelium cancers
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invasion46 and poor prognosis117 in patients with
pancreatic cancer. Knockdown of GPC1 in human
colon carcinoma cell lines resulted in a decrease in
invasion and migration.111 In patients with glioblastoma, elevated GPC1 expression was correlated with
tumor dissemination and shorter overall survival.178
The use of GPC1 antibodies as a diagnostic tool to
detect circulating tumor cells and exosomes, as well as
labeling of cancer cells in situ, is an active area of
investigation.19,110,131,166,177,218
Glypican-3 is found to be downregulated in breast,
lung, ovary, and mesothelium cancers.86 By contrast,
glypican-3 is overexpressed in hepatocellular, gastric,
ovarian, and lung squamous cell carcinomas, and
melanomas.153 In hepatocellular carcinoma, glypican-3
is actively investigated as a tool for diagnosis and
treatment.67
Cancer Cell Mechanotransduction
Interstitial ﬂow (IF) is enhanced in tumors due to
the leaky nature of tumor vasculature and increased
interstitial pressure in the tumor microenvironment.146
This enhanced ﬂow has been shown to alter the
migration and invasiveness of several types of
cancers.70,82,145,169,171,188 The role of the GCX as a
mechanosensor for IF has only recently begun to be
investigated. Our previous review200 looked at the
in vitro work of Qazi et al.169 showing IF signiﬁcantly
increased migration of a highly metastatic kidney cell
line (SN12L1). The same levels of ﬂow did not increase
migration in a low metastatic kidney carcinoma cell
line (SN12C). The effect was completely inhibited by
removal of either HS with heparinase or HA with
hyaluronidase. This work was recently extended to an
animal model to investigate the possibility that cancer
cell GCX components mediate metastasis. Qazi
et al.170 implanted SN12L1 cells in the renal capsule of
mice and assessed metastatic colonization to distant
organs. They used shRNA to knockdown NDST1 in
SN12L1 cells thus suppressing synthesis of HS. This
resulted in a 95% reduction in metastasis of tumors
formed by knockdown cells compared to tumors
formed by unmodiﬁed cells (wild type). In addition,
they found that HS deﬁcient tumors had well-deﬁned
boundaries and did not invade the surrounding normal
tissue, while wild type tumors had poorly deﬁned
margins and aggressively invaded the surrounding tissue.
Kingsmore et al.96 used patient-derived xenograft
models to determine the effect of high ﬂow on invasiveness of glioblastoma stem cells. They observed
increased invasion into high ﬂow regions compared to
low ﬂow regions in two of the three patient-derived cell
lines. Examining the cell lines in vitro, they found that
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the ﬂow response could be occurring through two
mechanisms: autologous chemotaxis mediated by
CXCR4/CXCL2, or mechanotransduction mediated
by CD44. Characterization of each cell line revealed
different percentages of CXCR4, CXCL2, and CD44
expressing cells indicating that subpopulations of
glioblastoma stem cells could respond to ﬂow via either
mechanism within a single patient.
Moran et al.142 investigated the speciﬁc proteins
that link surface GAGs that sense IF to the cancer cell
body where mechanotransduction resulting in
increased migration occurs. They measured the
expression of GPC1, SDC1, and CD44 in high
(SN12L1) and low (SN12C) metastatic kidney cell lines
and found signiﬁcantly higher GPC1 levels in the high
metastatic cell line. Knockdown of GPC1 by siRNA
resulted in signiﬁcant inhibition of ﬂow-induced
migration in the SN12L1 cell line. While the baseline
(static) protein expression of CD44 was not different
between SN12L1 and SN12C cells, this group has
previously shown that 4 h of ﬂow signiﬁcantly
increased CD44 gene expression in SN12L1 cells and
that blocking CD44 expression resulted in blocking
ﬂow-induced migration.169 Recently, they investigated
the possibility that the other HA surface receptor,
RHAMM, could also act as the mechanical link
between HA and the cell. They found increased levels
of RHAMM in SN12L1 compared to SN12C, and
knockdown of RHAMM by siRNA signiﬁcantly reduced ﬂow-induced migration in the SN12L1 cell line
(unpublished data). A recent study by Mele et al.130
found that RHAMM knockdown slowed tumor
growth and inhibited metastasis of colorectal cancer
cells in a mouse model.
In summary, diﬀerential expression and modiﬁcation of GCX components appear to play key roles in
cancer progression. Cell-associated and extracellular
matrix HA and its cell-surface receptors CD44 and
RHAMM are upregulated in most cancers and are
associated with poor prognosis. Heparanase mediated
shedding of HS on SDC1 enables growth factor in the
tumor microenvironment to access receptors and
activate cell signaling that fosters tumor growth and
progression. On the other hand, HS on GPC1 acts as a
mechanosensor for IF that alters migration and invasiveness in some types of cancer. Finally, abnormal
glycosylation18,143 and GAG modiﬁcation by
enzymes35,71 (e.g. Heparanase, sulf-1) are actively
investigated as key mechanisms in tumor growth and
metastasis.
Cancer Metastasis (Endothelial Cell Glycocalyx)
The major cancer metastatic steps from a solid
tumor include migration of tumor cells from the
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FIGURE 15. Endothelial surface glycocalyx labeled with FITC-anti-HS (green) on a rat mesenteric microvessel (left panel) without
breast cancer cell adhesion (left panels), at initial adhesion (middle panel, red spots are cancer cells) and after 45 min perfusion
(right panel). Reprinted from Ref. 21.
TABLE 2. Drugs that rescue the GCX.
Compound
Albumin/S1P
Sulodexide
Rhamnan Sulfate
Sevoflurane
Biomimetic Nanoparticles
ALM BHB/M P-188
Blueberry Metabolites
Empagliflozin
Metformin

Possible mechanisms

References

Regenerate GCX, inhibit shedding
Supplement GCX, inhibit degrading enzymes
Enhances HS synthesis
Inhibit shedding, increase GCX regeneration
Replace shed GCX
Inhibit shedding
Regenerate GCX
Regenerate GCX
Regenerate GCX

4,11,132,235,238
30,112,123,193,194,214
23,156,197
5,24,93,113
223,243
206
13,16,38
34,83
8,53,102,204,214

S1P sphingosine-1 phosphate, ALM adenosine + lidocaine + Mg, BHB/M beta-hydroxybutryrate + melatonin, P-188 poloxamer 188.

original site to nearby microvessels, intravasation into
the blood circulation through the microvessel wall,
arrest and adhesion to the microvasculature at a distant organ, interaction with the ECs forming the
microvessel wall and extravasation from the leaky
endothelial barrier to the surrounding tissue, survival,
proliferation and formation of a new colony. While

cancer cell GCX enhances cancer cell migration in the
tissue during its metastasis, damage of endothelial
GCX has been found during tumor cell adhesion and
extravasation. An in vivo study by Cai et al.21 showed
that adhesion of malignant breast cancer cell MDAMB-231 to microvessel walls degrades endothelial
GCX in a timely manner (Fig. 15). Preservation of the
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GCX either by a plasma glycoprotein orosomucoid21
or sphingosine-1-phosphate (S1P),245 and inhibition of
VEGF receptor (KDR/Flk-1)187 can reduce the tumor
cell adhesion. In vitro studies also found that breast
cancer cell adhesion to and transmigration across an
in vitro blood–brain barrier signiﬁcantly destroy the
endothelial GCX but not the cancer cell GCX.56 Although the mechanism by which cancer cells degrade
the endothelial GCX is not completely understood,
integrin b4 signaling65 enhanced ErbB2-dependent
expression of VEGF by tumor cells55 is a likely reason.
VEGF can degrade GCX21,56 to expose more cell and
extracellular matrix adhesion molecules, e.g. E-selectin,172 at the endothelium and underneath the
basement membrane, e.g. laminin,55 for tumor cell
adhesion and transmigration.
Drugs and Strategies to Rescue the Glycocalyx
A previous review200 summarized a number of
emerging approaches to rescue and/or stabilize the
GCX. Below we update with recent developments on
these and newer approaches. These are summarized in
Table 2. Save for a few exceptions, the effects of the
drugs discussed below on the GCX have not yet been
tested in human trials and the results derive from
in vitro and/or animal studies.
Albumin/S1P
The administration of plasma (albumin) is an
established practice in the treatment of massive hemorrhage and trauma. A recent review summarizes the
role of plasma in protecting the endothelium.11 A key
mediator in the effect of plasma on the endothelial
GCX may be albumin-bound S1P, which has been
shown to inhibit the shedding of SDC1 and regenerate
the GCX.235,238 Recently, Mensah et al.132 combined
S1P with exogenous HS to restore expression of Connexin 43 and interendothelial communication after
GCX degradation with heparinese III in vitro. While
both S1P and exogenous HS restored HS after degradation, only the combination of both agents was found
to restore interendothelial communication. Alves
et al.4 used an in vivo rat model of hemorrhagic shock
and resuscitation (HSR) to show that S1P reduces
microvascular leakage induced by HSR and protects
against GCX degradation. In vitro, they also show that
S1P protects against mitochondrial dysfunction-induced endothelial barrier dysfunction by acting
through mitochondrial complex III.
Sulodexide
Sulodexide is a highly puriﬁed GAG extracted from
the porcine intestinal mucosa. It is composed of 80%
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fast-moving heparin (a HS mimetic) and 20% dermatan sulfate and is available for oral, intramuscular,
and intravenous administration. Sulodexide has been
applied in clinical trials for the treatment of CVD and
diabetic nephropathy.30 Song and Goligorsky193
hypothesize that the superior effects of sulodexide are
due to its dual action: supplementation of GCX components, and inhibition of GCX degrading enzymes.
Fast-moving heparin inhibits heparanase while dermatan sulfate blocks the pro-MMP-9 molecule from
changing into the active form.
The eﬀect of sulodexide on endothelial function was
recently assessed by Li et al.112 in the balloon-injury
carotid artery model. Electron microscopy showed that
sulodexide reconstituted the GCX structure thus preserving endothelial function. The authors found that
sulodexide treatment increased eNOS levels, reduced
endothelial hyperplasia, inhibited platelet aggregation,
decreased expression of CD31, ICAM-1, and VCAM1, and reduced the inﬁltration of CD68-positive cells.
Van Haare et al.214 studied the effects of a 4-week
sulodexide treatment on microvascular perfusion
capacity of high fat diet-fed rats. They showed that
sulodexide restored the hyperemic response to adenosine in myocardial perfusion, which was blunted by the
high fat diet in control animals.
Degradation of the GCX is an early event in sepsis
which contributes to high mortality. Song et al.194 used
sulodexide to accelerate GCX restoration which
resulted in reduced vascular permeability and improved animal survival in a mouse model of sepsis.
CVD patients treated with sulodexide show signiﬁcant improvements in peripheral venous pressure, patient-assessed quality of life scores, and ulcer healing,
along with reductions plasma concentrations of MMP9, IL-6, and MCP-1, and reductions in other clinical
signs and symptoms.123
Rhamnan Sulfate
Suzuki and Terasawa197 recently reviewed the many
beneﬁcial biological activities of rhamnan sulfate (RS),
a sulfated polysaccharide extracted from the green algae M. nitidum. RS is found to have antiviral and
antithrombotic activities. It mitigates the high-fat diet
induced elevation of LDL cholesterol, and the postprandial increase in blood glucose level in healthy
human subjects. RS also has anti-inﬂammatory effects
on endothelial cells: it suppresses the elevation of tissue
factor and vWF in TNF-a or thrombin-induced
inﬂammation of ECs.156 We have previously shown
that RS enhances the GCX and reduces LDL permeability of cultured ECs.23 Recently, Aaron Baker’s lab
studied the effects of oral rhamnan sulfate on a mouse
model of atherosclerosis and found signiﬁcant reduc-
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tions in vascular inﬂammation and atherosclerotic
plaque formation (unpublished data).
Sevoﬂurane
Sevoﬂurane, a volatile anesthetic, has been shown to
protect the GCX during ischemia and reperfusion (IR).
Annecke et al.5 ﬁrst showed that ischemia led to
shedding of HS and SDC1, and degradation of the
GCX in isolated guinea pig hearts. Treatment with
sevoﬂurane before or after IR was found to attenuate
shedding of HS and SDC1. Treatment pre- plus postIR with sevoﬂurane was found to also preserve the
GCX structure. Chappell et al.24 showed sevoﬂurane
pretreatment also reduced leukocyte and platelet
adhesion after IR. In a study on Sprague–Dawley rats,
Li et al.113 showed sevoﬂurane reduced the shedding of
HS and SDC1, and preserved the endothelial GCX in
the liver following hepatic ischemia. The mechanisms
by which sevoﬂurane inhibitis GCX shedding in IR are
not well understood. Annecke et al.5 found that
sevoﬂurane treatment reduced the release of cathepsin
B, a protease stored in lysosomes and associated with
degradation of extracellular matrix and inﬂammatory
diseases. A recent study on rat aortas found that
sevoﬂurane promoted regeneration of the GCX by
upregulating the sialytransferase ST6Gal-1.93
Biomimetic Nanoparticles and Surfaces
Wodicka et al.223 developed a coating composed of
a dermatan sulfate backbone containing selectinbinding peptides to target endothelium with exposed
adhesion molecules due to loss of the GCX. The
coating was shown to reduce platelet activation and
binding to ECs in vitro. In an in vivo mouse model of
deep vein thrombosis the coating reduced thrombus
formation without decreasing the whole blood clotting
time, suggesting its potential to overcome the negative
side effects of standard anticoagulant therapies such as
heparin.
Liposomal nanocarriers of preassembled GCX have
been developed by the Goligorsky Lab.243 The
nanocarriers restored mechanically-induced NO production in cultured ECs pretreated with heparinase III.
The ﬂow-induced vasodilatation of mesenteric arteries
with degraded GCX was also restored after perfusion
with the nanocarriers.
Others
Because of increased recognition of the role of the
GCX as a key mediator in vascular diseases, drugs and
natural compounds previously shown to have beneﬁcial properties are now being investigated for their ef-

fects on the GCX. Below we summarize some recent
developments.
Torres Filho et al.206 tested three drugs previously
shown to improve outcomes after ischemia and hemorrhage for their effect on the GCX in a rat model of
hemorrhagic shock and resuscitation. They found that
all three compounds tested, adenosine + lidocaine + Mg (ALM), beta-hydroxybutryrate + melatonin (BHB/M), and poloxamer 188 (P-188)
signiﬁcantly restored the GCX thickness compared to
resuscitation with lactated Ringer’s solution. Lower
plasma SDC1 levels were also found with all three
drugs. While the mechanisms by which these drugs
restore the GCX are unknown, it is suggested that they
may counteract the production of reactive oxygen
species and oxidative stress that leads to GCX shedding.
Blueberry metabolites have been shown to attenuate
endothelial dysfunction in an in vitro model of lipoxocity,16 and clinical studies support a cardio-protective
role of blueberries in individuals with metabolic syndrome.13 Recently, Cutler et al.38 showed that blueberry metabolites restore GAGs, and reduce gene
expression of inﬂammatory markers and monocyte
binding on human aortic ECs derived from diabetic
patients, suggesting that some of the beneﬁcial effects
of blueberries are due to protection and restoration of
the GCX.
Empagliﬂozin is a sodium-glucose co-transporter-2
used to treat type 2 diabetes mellitus shown in clinical
trials to signiﬁcantly reduce cardiovascular events in
addition to improving glycemic control. Cooper et al.34
recently showed that empagliﬂozin restores the GCX
on human abdominal aortic ECs (HAAECs) after
degradation with heparinase III. In addition, empagliﬂozin restored the ﬂow-induced elongation, and
inhibited leukocyte cell adhesion to HAAECs with
degraded GCX. A new clinical trial83 found that
treatment with empagliﬂozin showed greater
improvement of vascular markers and endothelial
GCX thickness than insulin treatment in patients with
type 2 diabetes mellitus.
Metformin is the most popular anti-diabetic drug in
the United States and has been shown to have vasculoprotective8 and anticancer102 properties in type 2
diabetes patients independent of its glucose lowering
effects. Eskens et al.53 subjected a mouse model of type
2 diabetes to a 2-week metformin treatment and found
improved endothelial GCX barrier properties compared to the untreated group. Notably, this improvement occurred without any effect on blood glucose
levels. In the same sulodexide study cited above, Van
Haare et al.214 showed that metformin was as effective
as sulodexide in restoring the hyperemic response to
adenosine in myocardial perfusion in high-fat fed rats.
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More recently, Targosz-Korecka et al.204 found in an
in vitro study that metformin treatment restores the
GCX, downregulates surface expression of adhesion
molecules ICAM and E-selectin, and reduces stiffness
of ECs grown in high glucose. In addition, they found
that treatment with metformin reduced the adhesive
interaction between ECs and human lung carcinoma
cells. It is suggested that both the regeneration of the
endothelial GCX and downregulation of adhesion
molecules may contribute to the antimetastatic effects
of metformin.
Drugs and Strategies to Target the Glycocalyx
for Cancer Treatment
Carrier-Mediated Drug Delivery Systems
Because many cancer cells overexpress HA receptors CD44 and RHAMM, targeting of these using the
HA molecule itself has been used to deliver cytotoxic
agents directly to cancer cells. For example, nimesulide
is a hydrophobic COX-2 inhibitor anti-inﬂammatory
known to also inhibit tumor growth in various types of
cancer by inducing apoptosis. Jian et al.89 used an HAnimesulide conjugate to target CD44-overexpressing
HT-29 colorectal cancer cells in a mouse model
improving the drug’s selectivity and solubility. In vitro
HA-nimesulide increased apoptosis in HT-29 cells to
47.1%, compared to 2.9% in untreated cells. Tumor
growth was inhibited by 82.3% in mice treated with
HA-nimesulide, compared to control, whereas it was
inhibited by 55.9% in mice treated with free nimesulide. Yang et al.228 used HA conjugated with folic
acid to form micelles that were then loaded with doxorubicin (DOX). In vitro cytotoxicity tests revealed
that the DOX-loaded micelles were less toxic to tumor
cells than free DOX, likely because free DOX could
diffuse quickly into the cells while the micelles had to
be internalized via endocytosis, delaying the release of
DOX into the cells. However, when the micelles were
used in nude mice bearing human liver cancer cells
tumors, which express CD44, they resulted in improved targetability of DOX to the tumors. Zhong
et al.246 developed HA micelles loaded with paclitaxel
to successfully inhibit tumor growth of MCF-7 human
breast tumor xenografts in mice.
Antibody-Based Therapies
Antibody–drug conjugates (ADCs) are a targeted
therapy wherein a cytotoxic agent is linked to an
antibody. A number of ADCs have been developed
that target GCX components that are overexpressed in
cancer cells. Matsuzaki et al.127 developed a novel antiGPC1 antibody and conjugated it to the cytotoxic
agent monomethyl auristatin F (MMAF) for the
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treatment of uterine cervical cancer. In preclinical
studies, the GPC1-ADC was internalized and was
cytotoxic in HeLa and ME180, two uterine cervical
cancer cell lines that overexpress GPC1, while it had no
effect on an ovarian cancer cell line that did not express GPC1. The GPC1-ADC also inhibited tumor
growth in a murine xenograph model. The same group
developed a different GPC1-ADC, also conjugated to
MMAF, which showed tumor growth inhibition in
patient-derived tumor models of pancreatic cancer.154
Indatuximab ravtansine is an ADC that links an
anti-SDC1 antibody to the cytotoxic agent maytansine. It was recently shown to strongly inhibit tumor
growth in a high SDC1-expressing xenograph model of
triple-negative breast cancer.184 The ﬁrst clinical study
on patients with relapsed and/or refractory multiple
myeloma showed over 75% of patients achieved
stable disease.87
Antibody-dependent cellular cytotoxicity (ADCC)
is a mechanism of immune defense in which natural
killer cells lyse target cells whose surface antigens have
been bound by speciﬁc antibodies. Several therapeutic
antibodies against glypican-3 have been developed for
treatment of hepatocelullar carcinoma which features
overexpression of glypican-3.230 The recombinant
monoclonal antibody GC33 (codrituzumab) binds to
the juxtamembrane domain of glypican-3 and induces
ADCC. It was well tolerated and had antitumor effects
in phase I trials. Although GC33 did not show beneﬁts
in a phase II trial, a phase I trial of the combination of
GC33 and an immune checkpoint targeting antibody is
currently in progress.153 Harada et al.73 recently
developed an anti-GPC1 antibody for the treatment of
esophageal squamous cell carcinoma. The antibody
inhibited tumor growth via ADCC and decreased
angiogenesis in patient derived tumor xenograft models.
Heparanase Inhibitors
Heparanase is upregulated in all major types of
human cancer and is associated with increased tumor
size, tumor angiogenesis, and metastasis.164 This has
stimulated efforts to identify or design heparanase inhibitors for use in cancer therapy. Heparin derivatives
and HS mimetics constitute a major class of heparanase inhibitors (recently reviewed by Lanzi and
Cassinelli104) and several of these have progressed into
clinical trials. The synthesis of small molecule heparanase inhibitors with high selectivity is also an active
area of research.6,88
Speciﬁc Editing of the Glycan Structure
An emerging strategy is the design of tools that allow for precise editing of the GCX by targeting the
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glycan structure. These include small molecule inhibitors of glycan biosynthesis, modiﬁcation of glycoproteins,
and
CRISPR-based
editing
of
glycosyltransferases. Buﬀone and Weaver18 recently
reviewed these new strategies for GCX editing.
Munkley and Scott reviewed the targeting of glycan
sialylation which is upregulated in cancer.144

FUTURE DIRECTIONS
As we have seen in this review, many important
developments in our basic understanding of GCX
structure, function and role in diseases have been described since the 2007 review.220 The future is wide
open for continued GCX research. A few suggestions
derived from this review are outlined below:
1. The implications of the Michel–Weinbaum revised
Starling hypothesis for controlling ﬂuid balance in
perioperative settings where acute normovolemic
hemodilution is required to compensate for blood
loss or hypovolemia should be pursued as well as
the role of trapped microdomains in muscle tissue.
2. The importance of HSPG GPC1 as the upstream
mechanosensor in shear-induced NO production
after longer exposures to shear (minutes to hours)
has been reviewed, but the role of the GCX in NO
production after acute (seconds to minutes)
changes in shear has not been investigated.
3. The mechanism by which substrate stiffness sup
presses GPC1 expression leading to endothelial
dysfunction has not been thoroughly investigated.
4. While it has been shown that GPC1 is suppressed
in a mouse model of aging, a hypertensive mouse
or rat model has not been considered and these
questions have not been addressed in human
subjects.
5. STORM imaging of the GCX on ECs should be
extended to examine additional GAGs and proteoglycans as well as a variety of cell types both
in vitro and in vivo.
6. The role of GCX components in infectious dis
eases is understudied. A question related to the
recent SARS COV-2 (COVID -19) virus is whether GAGs/proteoglycans mediate binding of the
virus to the host cell as has been shown for SARS
COV-1. There are many other questions.
7. Does restoration of the GCX on ECs in inﬂam
matory environments really limit or reverse
atherosclerosis and related cardiovascular diseases? This should be tested extensively in animals
and, if promising, in humans.
8. An important role for IF in cancer metastasis has
been suggested by recent studies. Because

mechanotransduction of IF by the cancer cell
GCX is involved, it will be important to determine
which cancers are sensitive to IF and which GCX
components are the sensors and transducers of IF.
9. Degradation of the endothelial GCX has been
suggested by recent studies as a requirement for
cancer cell extravasation from the vasculature
during metastasis. More extensive animal studies
are required to demonstrate the importance of this
mechanism.
10. While there has been extensive recent research
to develop GCX preserving or enhancing agents
for treatment of vascular and related diseases,
there is a great need for additional testing in animal models of diseases as pre-clinical preparation
for clinical trials.
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